UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
For the quarterly period ended
Commission file number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (IRS Employer Identification No.) | |
(Address of Principal Executive Offices) | (Zip Code) | |
(Registrant’s Telephone Number, Including Area Code) ( Not Applicable | ||
(Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Note: The common stock of the Registrant is also traded on the SWX Swiss Exchange.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:
Accelerated filer ☐ | ||
Non-accelerated filer ☐ | Smaller reporting company | |
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class | Outstanding at June 30, 2020 | |
Common Stock, $0.01 par value per share |
3M COMPANY
Form 10-Q for the Quarterly Period Ended June 30, 2020
TABLE OF CONTENTS | BEGINNING | |
Index to Financial Statements: | ||
3 | ||
4 | ||
5 | ||
6 | ||
7 | ||
10 | ||
13 | ||
14 | ||
16 | ||
18 | ||
Note 7. Supplemental Equity and Comprehensive Income Information | 19 | |
23 | ||
Note 9. Marketable Securities and Held-to-Maturity Debt Securities | 23 | |
24 | ||
25 | ||
26 | ||
33 | ||
35 | ||
50 | ||
53 | ||
Management’s Discussion and Analysis of Financial Condition and Results of Operations | ||
Index to Management’s Discussion and Analysis: | ||
56 | ||
65 | ||
69 | ||
75 | ||
Cautionary Note Concerning Factors That May Affect Future Results | 81 | |
81 | ||
82 | ||
83 | ||
83 | ||
87 | ||
88 | ||
88 | ||
88 | ||
88 |
2
3M COMPANY
FORM 10-Q
For the Quarterly Period Ended June 30, 2020
PART I. Financial Information
Item 1. Financial Statements.
3M Company and Subsidiaries
Consolidated Statement of Income
(Unaudited)
| Three months ended |
| Six months ended |
| |||||||||
June 30, | June 30, | ||||||||||||
(Millions, except per share amounts) |
| 2020 |
| 2019 |
| 2020 | 2019 |
| |||||
Net sales | $ | | $ | | $ | | $ | | |||||
Operating expenses | |||||||||||||
Cost of sales |
| |
| |
| |
| | |||||
Selling, general and administrative expenses |
| |
| |
| |
| | |||||
Research, development and related expenses |
| |
| |
| |
| | |||||
Gain on sale of businesses | ( | — | ( | ( | |||||||||
Total operating expenses |
| |
| |
| |
| | |||||
Operating income |
| |
| |
| |
| | |||||
Other expense (income), net |
| |
| |
| |
| | |||||
Income before income taxes |
| |
| |
| |
| | |||||
Provision for income taxes |
| |
| |
| |
| | |||||
Net income including noncontrolling interest | $ | | $ | | $ | | $ | | |||||
Less: Net income (loss) attributable to noncontrolling interest |
| ( |
| |
| ( |
| | |||||
Net income attributable to 3M | $ | | $ | | $ | | $ | | |||||
Weighted average 3M common shares outstanding — basic |
| |
| |
| |
| | |||||
Earnings per share attributable to 3M common shareholders — basic | $ | | $ | | $ | | $ | | |||||
Weighted average 3M common shares outstanding — diluted |
| |
| |
| |
| | |||||
Earnings per share attributable to 3M common shareholders — diluted | $ | | $ | | $ | | $ | | |||||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
3
3M Company and Subsidiaries
Consolidated Statement of Comprehensive Income
(Unaudited)
| Three months ended |
| Six months ended |
| ||||||||||
June 30, | June 30, | |||||||||||||
(Millions) |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| |||||
Net income including noncontrolling interest | $ | | $ | | $ | | $ | | ||||||
Other comprehensive income (loss), net of tax: | ||||||||||||||
Cumulative translation adjustment |
| |
| |
| ( |
| | ||||||
Defined benefit pension and postretirement plans adjustment |
| |
| |
| |
| | ||||||
Cash flow hedging instruments |
| ( |
| ( |
| |
| ( | ||||||
Total other comprehensive income (loss), net of tax |
| |
| |
| ( |
| | ||||||
Comprehensive income (loss) including noncontrolling interest |
| |
| |
| |
| | ||||||
Comprehensive (income) loss attributable to noncontrolling interest |
| |
| ( |
| |
| ( | ||||||
Comprehensive income (loss) attributable to 3M | $ | | $ | | $ | | $ | | ||||||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
4
3M Company and Subsidiaries
Consolidated Balance Sheet
(Unaudited)
| June 30, |
| December 31, |
| |||
(Dollars in millions, except per share amount) |
| 2020 |
| 2019 |
| ||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | | $ | | |||
Marketable securities — current |
| |
| | |||
Accounts receivable — net of allowances of $ |
| |
| | |||
Inventories | |||||||
Finished goods |
| |
| | |||
Work in process |
| |
| | |||
Raw materials and supplies |
| |
| | |||
Total inventories |
| |
| | |||
Prepaids | | | |||||
Other current assets |
| |
| | |||
Total current assets |
| |
| | |||
Property, plant and equipment |
| |
| | |||
Less: Accumulated depreciation |
| ( |
| ( | |||
Property, plant and equipment — net |
| |
| | |||
Operating lease right of use assets | | | |||||
Goodwill |
| |
| | |||
Intangible assets — net |
| |
| | |||
Other assets |
| |
| | |||
Total assets | $ | | $ | | |||
Liabilities | |||||||
Current liabilities | |||||||
Short-term borrowings and current portion of long-term debt | $ | | $ | | |||
Accounts payable |
| |
| | |||
Accrued payroll |
| |
| | |||
Accrued income taxes |
| |
| | |||
Operating lease liabilities — current | | | |||||
Other current liabilities |
| |
| | |||
Total current liabilities |
| |
| | |||
Long-term debt |
| |
| | |||
Pension and postretirement benefits |
| |
| | |||
Operating lease liabilities | |
| | ||||
Other liabilities |
| |
| | |||
Total liabilities | $ | | $ | | |||
Commitments and contingencies (Note 14) | |||||||
Equity | |||||||
3M Company shareholders’ equity: | |||||||
Common stock par value, $ | $ | | $ | | |||
Shares outstanding - June 30, 2020: | |||||||
Shares outstanding - December 31, 2019: | |||||||
Additional paid-in capital |
| |
| | |||
Retained earnings |
| |
| | |||
Treasury stock, at cost: |
| ( |
| ( | |||
Shares at June 30, 2020: | |||||||
Shares at December 31, 2019: | |||||||
Accumulated other comprehensive income (loss) |
| ( |
| ( | |||
Total 3M Company shareholders’ equity |
| |
| | |||
Noncontrolling interest |
| |
| | |||
Total equity | $ | | $ | | |||
Total liabilities and equity | $ | | $ | | |||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
5
3M Company and Subsidiaries
Consolidated Statement of Cash Flows
(Unaudited)
| Six months ended |
| |||||
June 30, | |||||||
(Millions) |
| 2020 |
| 2019 |
| ||
Cash Flows from Operating Activities | |||||||
Net income including noncontrolling interest | $ | | $ | | |||
Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities | |||||||
Depreciation and amortization |
| |
| | |||
Company pension and postretirement contributions |
| ( |
| ( | |||
Company pension and postretirement expense |
| |
| | |||
Stock-based compensation expense |
| |
| | |||
Gain on sale of businesses | ( | ( | |||||
Deferred income taxes |
| |
| ( | |||
Loss on deconsolidation of Venezuelan subsidiary |
| — |
| | |||
Changes in assets and liabilities | |||||||
Accounts receivable |
| |
| ( | |||
Inventories |
| ( |
| | |||
Accounts payable |
| ( |
| ( | |||
Accrued income taxes (current and long-term) |
| |
| ( | |||
Other — net |
| ( |
| | |||
Net cash provided by (used in) operating activities |
| |
| | |||
Cash Flows from Investing Activities | |||||||
Purchases of property, plant and equipment (PP&E) |
| ( |
| ( | |||
Proceeds from sale of PP&E and other assets |
| |
| | |||
Acquisitions, net of cash acquired |
| ( |
| ( | |||
Purchases of marketable securities and investments |
| ( |
| ( | |||
Proceeds from maturities and sale of marketable securities and investments |
| |
| | |||
Proceeds from sale of businesses, net of cash sold |
| |
| | |||
Other — net |
| |
| | |||
Net cash provided by (used in) investing activities |
| |
| ( | |||
Cash Flows from Financing Activities | |||||||
Change in short-term debt — net |
| ( |
| ( | |||
Repayment of debt (maturities greater than 90 days) |
| ( |
| ( | |||
Proceeds from debt (maturities greater than 90 days) |
| |
| | |||
Purchases of treasury stock |
| ( |
| ( | |||
Proceeds from issuance of treasury stock pursuant to stock option and benefit plans |
| |
| | |||
Dividends paid to shareholders |
| ( |
| ( | |||
Other — net |
| ( |
| ( | |||
Net cash provided by (used in) financing activities |
| ( |
| ( | |||
Effect of exchange rate changes on cash and cash equivalents |
| ( |
| ( | |||
Net increase (decrease) in cash and cash equivalents |
| |
| ( | |||
Cash and cash equivalents at beginning of year |
| |
| | |||
Cash and cash equivalents at end of period | $ | | $ | | |||
The accompanying Notes to Consolidated Financial Statements are an integral part of this statement.
6
3M Company and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
NOTE 1. Significant Accounting Policies
Basis of Presentation
The interim consolidated financial statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. These adjustments consist of normal, recurring items. The results of operations for any interim period are not necessarily indicative of results for the full year. The interim consolidated financial statements and notes are presented as permitted by the requirements for Quarterly Reports on Form 10-Q. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in its Annual Report on Form 10-K.
As described in Note 16, effective in the second quarter of 2020, the measure of segment operating performance used by 3M’s chief operating decision maker changed and, as a result, the Company’s disclosed measure of segment profit/loss has been updated. Also, effective in the first quarter of 2020, the Company changed its business segment reporting in its continuing effort to improve the alignment of businesses around markets and customers. Additionally, the Company consolidated the way it presents geographic area net sales by providing an aggregate Americas geographic region (combining former United States and Latin America and Canada areas). Information provided herein reflects the impact of these changes for all periods presented.
Use of estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company considered the coronavirus (COVID-19) related impacts on its estimates, as appropriate, within its consolidated financial statements and there may be changes to those estimates in future periods. 3M believes that the accounting estimates are appropriate after giving consideration to the increased uncertainties surrounding the severity and duration of the COVID-19 pandemic. Such estimates and assumptions are subject to inherent uncertainties which may result in actual amounts differing from these estimates.
Changes to Significant Accounting Policies
The following significant accounting policies have been added or changed as applicable since the Company’s 2019 Annual Report on Form 10-K as a result of adoption of new accounting pronouncements as described in the “New Accounting Pronouncements” section.
Accounts receivable and allowances: Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company maintains allowances for bad debts, cash discounts, and various other items. The allowances for bad debts and cash discounts are based on the best estimate of the amount of expected credit losses in existing accounts receivable and anticipated cash discounts. The Company determines the allowances based on historical write-off experience by industry and regional economic data, current expectations of future credit losses, and historical cash discounts. The Company reviews the allowances monthly. The allowances for bad debts as well as the provision for credit losses, write-off activity and recoveries for the periods presented are not material. The Company does not have any significant off-balance-sheet credit exposure related to its customers. The Company has long-term customer receivables that do not have significant credit risk, and the origination dates of which are typically not older than
Marketable securities: Marketable securities include available-for-sale debt securities and are recorded at fair value. Cost of securities sold use the first in, first out (FIFO) method. The classification of marketable securities as current or non-current is based on the availability for use in current operations. 3M reviews impairments associated with its marketable securities in accordance with the measurement guidance provided by ASC 320, Investments-Debt Securities and ASC 326-30, Available-for-Sale Debt Securities, when determining whether a decline in fair value below the amortized cost basis has resulted from a credit loss or other factors. An impairment relating to credit losses is recorded through an allowance for credit losses. The allowance is limited by the amount that the fair value is less than the amortized cost basis. A change in the allowance for credit losses is recorded into earnings in the period of the
7
change. Any impairment that has not been recorded through an allowance for credit losses is recorded through accumulated other comprehensive income as a component of shareholders’ equity. The factors considered in determining whether a credit loss exists can include the extent to which fair value is less than the amortized cost basis, changes in the credit quality of the underlying loan obligors, credit ratings actions, as well as other factors. When a credit loss exists, the Company compares the present value of cash flows expected to be collected from the debt security with the amortized cost basis of the security to determine what allowance amount, if any, should be recorded. Amounts are reclassified out of accumulated other comprehensive income and into earnings upon sale or a change in the portions of impairment related to credit losses and not related to credit losses.
Property, plant and equipment: 3M’s accounting policy with respect to property, plant and equipment, is disclosed in the Company’s notes to consolidated financial statements included in its most recent Annual Report on Form 10-K. In addition, 3M records capital-related government grants earned as reductions to the cost of property, plant and equipment; and associated unpaid liabilities and grant proceeds receivable are considered non-cash changes in such balances for purposes of preparation of statement of cash flows.
Foreign Currency Translation
Local currencies generally are considered the functional currencies outside the United States with the exception of 3M’s subsidiaries in Argentina, the economy of which was considered highly inflationary beginning in 2018, and accordingly the financial statements of these subsidiaries are remeasured as if their functional currency is that of their parent. Assets and liabilities for operations in local-currency environments are translated at month-end exchange rates of the period reported. Income and expense items are translated at average monthly currency exchange rates in effect during the period. Cumulative translation adjustments are recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity.
3M had a consolidated subsidiary in Venezuela, the financial statements of which were remeasured as if its functional currency were that of its parent because Venezuela’s economic environment is considered highly inflationary. The operating income of this subsidiary was immaterial as a percent of 3M’s consolidated operating income for the periods presented. In light of circumstances, including the country’s unstable environment and heightened unrest leading to sustained lack of demand, and expectation that these circumstances will continue for the foreseeable future, during May 2019, 3M concluded it no longer met the criteria of control in order to continue consolidating its Venezuelan operations. As a result, as of May 31, 2019, the Company began reflecting its interest in the Venezuelan subsidiary as an equity investment that does not have a readily determinable fair value. This resulted in a pre-tax charge of $
Earnings Per Share
The difference in the weighted average 3M shares outstanding for calculating basic and diluted earnings per share attributable to 3M common shareholders is a result of the dilution associated with the Company’s stock-based compensation plans. Certain options outstanding under these stock-based compensation plans were not included in the computation of diluted earnings per share attributable to 3M common shareholders because they would have had an anti-dilutive effect (
8
Earnings Per Share Computations
| Three months ended |
| Six months ended |
| |||||||||
June 30, | June 30, | ||||||||||||
(Amounts in millions, except per share amounts) |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| ||||
Numerator: | |||||||||||||
Net income attributable to 3M | $ | | $ | | $ | | $ | | |||||
Denominator: | |||||||||||||
Denominator for weighted average 3M common shares outstanding – basic |
| |
| |
| |
| | |||||
Dilution associated with the Company’s stock-based compensation plans |
| |
| |
| |
| | |||||
Denominator for weighted average 3M common shares outstanding – diluted |
| |
| |
| |
| | |||||
Earnings per share attributable to 3M common shareholders – basic | $ | | $ | | $ | | $ | | |||||
Earnings per share attributable to 3M common shareholders – diluted | $ | | $ | | $ | | $ | | |||||
New Accounting Pronouncements
See the Company’s 2019 Annual Report on Form 10-K for a more detailed discussion of the standards in the tables that follow, except for those pronouncements issued subsequent to the most recent Form 10-K filing date for which separate, more detailed discussion is provided below as applicable.
Standards Adopted During the Current Fiscal Year | |||||
Standard | Relevant Description | Effective Date for 3M | Impact and Other Matters | ||
ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (in conjunction with ASU Nos. 2018-19, 2019-04, 2019-05, 2019-11, and 2020-03) | Introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. Amends the current other-than-temporary impairment model for available-for-sale debt securities. For such securities with unrealized losses, entities will still consider if a portion of any impairment is related only to credit losses and therefore recognized as a reduction in income. | January 1, 2020 | Adopted using the modified retrospective approach. Adoption of this ASU did not have a material impact due to the nature and extent of 3M’s financial instruments in scope for this ASU (primarily accounts receivable) and the historical, current and expected credit quality of its customers as of the date of adoption. See Note 1 Significant Accounting Policies for updated applicable accounting policies. | ||
ASU No. 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement | Eliminates, amends, and adds disclosure requirements for fair value measurements, primarily related to Level 3 fair value measurements. | January 1, 2020 | This ASU relates to disclosure only. The nature and extent of 3M’s financial instruments in scope for this ASU (primarily Level 3 fair value measurements) are immaterial to 3M’s consolidated results of operations and financial condition. | ||
ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract | Aligns the accounting for implementation costs incurred in a cloud computing arrangement that is a service arrangement (i.e. hosting arrangement) with the guidance on capitalizing costs in ASC 350-40, Internal-Use Software | January 1, 2020 | Adopted on a prospective basis. Relevant capitalizable costs are included in prepaid expenses or other non-current asset, as applicable, prospectively beginning in 2020. | ||
9
Standards Issued and Not Yet Adopted | |||
Standard | Relevant Description | Effective Date for 3M | Impact and Other Matters |
ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740) | Eliminates certain existing exceptions related to the general approach in ASC 740 relating to franchise taxes, reducing complexity in the interim-period accounting for year-to-date loss limitations and changes in tax laws, and clarifying the accounting for transactions outside of business combination that result in a step-up in the tax basis of goodwill. | January 1, 2021 | 3M previously disclosed it does not expect this ASU to have a material impact on its consolidated results of operations and financial condition. |
ASU No. 2020-01, Clarifying the Interactions between Topic 321, Investments—Equity Securities, Topic 323, Investments—Equity Method and Joint Ventures, and Topic 815, Derivatives and Hedging | Clarifies when accounting for certain equity securities, a Company should consider observable transactions before applying or upon discontinuing the equity method of accounting for the purposes of applying the measurement alternative. Indicates when determining the accounting for certain derivatives, a Company should not consider if the underlying securities would be accounted for under the equity method or fair value option. | January 1, 2021 | 3M previously disclosed it does not expect this ASU to have a material impact on its consolidated results of operations and financial condition, but will apply such guidance, where applicable, to future circumstances. |
Relevant New Standards Issued Subsequent to Most Recent Annual Report
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides temporary optional expedients and exceptions to existing guidance on contract modifications and hedge accounting to facilitate the market transition from existing reference rates, such as LIBOR which is being phased out in 2021, to alternate reference rates, such as SOFR. The standard was effective upon issuance and allowed application to contract changes as early as January 1, 2020. The provisions have impact as contract modifications and other changes occur while LIBOR is phased out. The Company is in the process of evaluating the optional relief guidance provided within this ASU and is also reviewing its debt securities, bank facilities, derivative instruments and commercial contracts that utilize LIBOR as the reference rate. 3M will continue its assessment and monitor regulatory developments during the LIBOR transition period.
NOTE 2. Revenue
Contract Balances:
Deferred revenue primarily relates to revenue that is recognized over time for
Operating Lease Revenue:
Net sales includes rental revenue from durable medical devices as part of operating lease arrangements, which was $
10
Disaggregated revenue information:
The Company views the following disaggregated disclosures as useful to understanding the composition of revenue recognized during the respective reporting periods:
Three months ended | Six months ended | ||||||||||||
June 30, | June 30, | ||||||||||||
Net Sales (Millions) | 2020 |
| 2019 |
| 2020 |
| 2019 | ||||||
Abrasives | $ | | $ | | $ | | $ | | |||||
Automotive Aftermarket | | | | | |||||||||
Closure and Masking Systems | | | | | |||||||||
Electrical Markets | | | | | |||||||||
Industrial Adhesives and Tapes | | | | | |||||||||
Personal Safety | | | | | |||||||||
Roofing Granules | | | | | |||||||||
Other Safety and Industrial | | | | | |||||||||
Total Safety and Industrial Business Segment | $ | | $ | | $ | | $ | | |||||
Advanced Materials | $ | | $ | | $ | | $ | | |||||
Automotive and Aerospace | | | | | |||||||||
Commercial Solutions | | | | | |||||||||
Electronics | | | | | |||||||||
Transportation Safety | | | | | |||||||||
Other Transportation and Electronics | ( | | ( | ( | |||||||||
Total Transportation and Electronics Business Segment | $ | | $ | | $ | | $ | | |||||
Drug Delivery | $ | | $ | | $ | | $ | | |||||
Food Safety | | | | | |||||||||
Health Information Systems | | | | | |||||||||
Medical Solutions | | | | | |||||||||
Oral Care | | | | | |||||||||
Separation and Purification Sciences | | | | | |||||||||
Other Health Care | | | ( | ( | |||||||||
Total Health Care Business Group | $ | | $ | | $ | | $ | | |||||
Consumer Health Care | $ | | $ | | $ | | $ | | |||||
Home Care | | | | | |||||||||
Home Improvement | | | | | |||||||||
Stationery and Office | | | | | |||||||||
Other Consumer | | | | | |||||||||
Total Consumer Business Group | $ | | $ | | $ | | $ | | |||||
Corporate and Unallocated | $ | ( | $ | | $ | ( | $ | | |||||
Elimination of Dual Credit | ( | ( | ( | ( | |||||||||
Total Company | $ | | $ | | $ | | $ | | |||||
11
Three months ended June 30, 2020 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| — |
| | ||||||
Health Care | | | | | | |||||||||||
Consumer |
| |
| |
| |
| — |
| | ||||||
Corporate and Unallocated |
| ( |
| — |
| — |
| ( |
| ( | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| — |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | | $ | | ||||||
Six months ended June 30, 2020 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | — | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| — |
| | ||||||
Health Care | | | | — | | |||||||||||
Consumer |
| |
| |
| |
| — |
| | ||||||
Corporate and Unallocated |
| — |
| — |
| — |
| ( |
| ( | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| — |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | ( | $ | | ||||||
Three months ended June 30, 2019 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | — | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| — |
| | ||||||
Health Care | | | | — | | |||||||||||
Consumer |
| |
| |
| |
| |
| | ||||||
Corporate and Unallocated |
| |
| ( |
| ( |
| |
| | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| ( |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | — | $ | | ||||||
Six months ended June 30, 2019 | ||||||||||||||||
Net Sales (Millions) |
| Americas | Asia Pacific |
| Europe, Middle East and Africa |
| Other Unallocated |
| Worldwide | |||||||
Safety and Industrial | $ | | $ | | $ | | $ | ( | $ | | ||||||
Transportation and Electronics |
| |
| |
| |
| ( |
| | ||||||
Health Care | | | | — | | |||||||||||
Consumer |
| |
| |
| |
| — |
| | ||||||
Corporate and Unallocated |
| |
| — |
| — |
| — |
| | ||||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| — |
| ( | ||||||
Total Company | $ | | $ | | $ | | $ | ( | $ | | ||||||
Americas included United States net sales to customers of $
12
NOTE 3. Acquisitions and Divestitures
Refer to Note 3 in 3M’s 2019 Annual Report on Form 10-K for more information on relevant pre-2020 acquisitions and divestitures
Acquisitions:
3M makes acquisitions of certain businesses from time to time that are aligned with its strategic intent with respect to, among other factors, growth markets and adjacent product lines or technologies. Goodwill resulting from business combinations is largely attributable to the existing workforce of the acquired businesses and synergies expected to arise after 3M’s acquisition of these businesses.
2020 acquisitions:
There were
2019 acquisitions:
In February 2019, 3M completed the acquisition of the technology business of M*Modal for $
In October 2019, the Company completed the acquisition of all of the ownership interests of Acelity Inc. and its KCI subsidiaries and in the first quarter of 2020 paid certain consideration previously accrued under the terms of related agreements. Adjustments in 2020 to the purchase price allocation were approximately $
Divestitures:
3M may divest certain businesses from time to time based upon review of the Company’s portfolio considering, among other items, factors relative to the extent of strategic and technological alignment and optimization of capital deployment, in addition to considering if selling the businesses results in the greatest value creation for the Company and for shareholders. As discussed in Note 16 (Business Segments), gains/losses on sale of businesses are reflected in Corporate and Unallocated.
2020 divestitures:
In January 2020, 3M completed the sale of its advanced ballistic-protection business, formerly part of the Transportation and Electronics business, to Avon Rubber p.l.c for $
13
In May 2020, 3M completed the sale of substantially all of its drug delivery business, formerly part of the Health Care business, to an affiliate of Altaris Capital Partners, LLC for $
2019 divestitures:
During 2019, as described in Note 3 in 3M’s 2019 Annual Report on Form 10-K, the Company divested a number of businesses including: certain oral care technology comprising a business and the gas and flame detection business. 3M also reflected an earnout on a previous divestiture.
Operating income and held for sale amounts:
The aggregate operating income of these businesses was approximately $
| December 31, |
| ||
(Millions) |
| 2019 |
| |
Inventory |
| | ||
Property, plant and equipment | | |||
Intangible assets | | |||
In addition, approximately $
NOTE 4. Goodwill and Intangible Assets
There was no goodwill recorded from acquisitions during the first six months of 2020. The acquisition activity in the following table relates to the net impact of adjustments to the preliminary allocation of purchase price within the one year measurement period following prior acquisitions, which decreased goodwill by $
Goodwill
(Millions) | Safety and Industrial | Transportation and Electronics | Health Care | Consumer | Total Company | |||||||||||
Balance as of December 31, 2019 | $ | | $ | | $ | | $ | | $ | | ||||||
Acquisition activity | — | — | ( | — | ( | |||||||||||
Divestiture activity | — | ( | ( | — | ( | |||||||||||
Translation and other | ( | ( | ( | | ( | |||||||||||
Balance as of June 30, 2020 | $ | | $ | | $ | | $ | | $ | | ||||||
14
Accounting standards require that goodwill be tested for impairment annually and between annual tests in certain circumstances such as a change in reporting units or the testing of recoverability of a significant asset group within a reporting unit. At 3M, reporting units correspond to a division.
As described in Note 16, effective in the first quarter of 2020, the Company changed its business segment reporting. For any product changes that resulted in reporting unit changes, the Company applied the relative fair value method to determine the impact on goodwill of the associated reporting units, the results of which were immaterial. In conjunction with the change in segment reporting, 3M completed an assessment indicating
Acquired Intangible Assets
The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets, as of June 30, 2020, and December 31, 2019, follow:
| June 30, |
| December 31, |
| |||
(Millions) |
| 2020 |
| 2019 |
| ||
Customer related intangible assets | $ | | $ | | |||
Patents |
| |
| | |||
Other technology-based intangible assets |
| |
| | |||
Definite-lived tradenames |
| |
| | |||
Other amortizable intangible assets |
| |
| | |||
Total gross carrying amount | $ | | $ | | |||
Accumulated amortization — customer related |
| ( |
| ( | |||
Accumulated amortization — patents |
| ( |
| ( | |||
Accumulated amortization — other technology-based |
| ( |
| ( | |||
Accumulated amortization — definite-lived tradenames |
| ( |
| ( | |||
Accumulated amortization — other |
| ( |
| ( | |||
Total accumulated amortization | $ | ( | $ | ( | |||
Total finite-lived intangible assets — net | $ | | $ | | |||
Non-amortizable intangible assets (primarily tradenames) |
| |
| | |||
Total intangible assets — net | $ | | $ | | |||
Certain tradenames acquired by 3M are not amortized because they have been in existence for over
Amortization expense for the three and six months ended June 30, 2020 and 2019 follows:
| Three months ended |
| Six months ended |
| |||||||||
June 30, | June 30, | ||||||||||||
(Millions) |
| 2020 |
| 2019 |
| 2020 | 2019 |
| |||||
Amortization expense | $ | | $ | | $ | | $ | | |||||
Expected amortization expense for acquired amortizable intangible assets recorded as of June 30, 2020:
Remainder of | After |
| ||||||||||||||||||||
(Millions) | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 |
| ||||||||||||||
Amortization expense | $ | | $ | | $ | | $ | | $ | | $ | | $ | | ||||||||
15
The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from estimated amounts due to additional intangible asset acquisitions, changes in foreign currency exchange rates, impairment of intangible assets, accelerated amortization of intangible assets and other events. 3M expenses the costs incurred to renew or extend the term of intangible assets.
NOTE 5. Restructuring Actions
2020 Restructuring Actions:
Divestiture-Related Restructuring
During the second quarter of 2020, following the divestiture of substantially all of the drug delivery business (see Note 3) management approved and committed to undertake certain restructuring actions addressing corporate functional costs and manufacturing footprint across 3M in relation to the magnitude of amounts previously allocated/burdened to the divested business. These actions affected approximately
(Millions) |
| Second Quarter 2020 |
| |
Cost of sales | $ | | ||
Selling, general and administrative expenses |
| | ||
Research, development and related expenses |
| | ||
Total operating income impact | $ | | ||
Divestiture-related restructuring actions, including cash and non-cash impacts, follow:
(Millions) |
| Employee-Related |
| Asset-Related and Other |
| Total |
| |||
Expense incurred in the second quarter of 2020 | $ | | $ | | $ | | ||||
Non-cash changes | — | ( | ( | |||||||
Accrued divestiture-related restructuring action balances as of June 30, 2020 | $ | | $ | | $ | | ||||
Remaining activities related to this divestiture-related restructuring are expected to be largely completed through the second quarter of 2021.
Other Restructuring
Additionally, in the second quarter of 2020, management approved and committed to undertake certain restructuring actions addressing structural enterprise costs and operations in certain end markets as a result of the COVID-19 pandemic and related economic impacts. These actions affected approximately
(Millions) |
| Second Quarter 2020 |
| |
Cost of sales | $ | | ||
Selling, general and administrative expenses |
| | ||
Research, development and related expenses |
| | ||
Total operating income impact | $ | | ||
16
The business segment operating income impact of these restructuring charges are summarized by business segment as follows:
Second Quarter 2020 | ||||||||||
(Millions) |
| Employee-Related |
| Asset-Related |
| Total |
| |||
Safety and Industrial | $ | | $ | — | $ | | ||||
Transportation and Electronics | | — | | |||||||
Health Care | | — | | |||||||
Consumer | | — | | |||||||
Corporate and Unallocated |
| — |
|
| | |||||
Total Operating Expense | $ | | $ | | $ | | ||||
Restructuring actions, including cash and non-cash impacts, follow:
(Millions) |
| Employee-Related |
| Asset-Related |
| Total |
| |||
Expense incurred in the second quarter of 2020 | $ | | $ | | $ | | ||||
Non-cash changes | — | ( | ( | |||||||
Accrued restructuring action balances as of June 30, 2020 | $ | | $ | — | $ | | ||||
Remaining activities related to this restructuring are expected to be largely completed through the second quarter of 2021.
2019 Restructuring Actions:
As described in Note 5 in 3M’s 2019 Annual Report on Form 10-K, during the second quarter of 2019, in light of slower than expected 2019 sales, management approved and committed to undertake certain restructuring actions. These actions impacted approximately
(Millions) |
| Second Quarter 2019 |
| |
Cost of sales | $ | | ||
Selling, general and administrative expenses |
| | ||
Research, development and related expenses |
| | ||
Total operating income impact | | |||
Other expense (income), net | | |||
Total income before taxes impact | $ | | ||
The operating income impact of these restructuring charges are summarized by business segment as follows:
Second Quarter 2019 | ||||||||||
(Millions) |
| Employee-Related |
| Asset-Related |
| Total |
| |||
Safety and Industrial | $ | | $ | — | $ | | ||||
Transportation and Electronics | | — | | |||||||
Health Care | | — | | |||||||
Consumer | | — | | |||||||
Corporate and Unallocated |
| |
| |
| | ||||
Total Operating Expense | $ | | $ | | $ | | ||||
The second quarter 2019 actions included a voluntary early retirement incentive (further discussed in Note 11), the charge for which is included in other expense (income), net above.
17
Restructuring action activity from 2019, which includes both second and fourth quarter actions, including cash and non-cash impacts, follow:
(Millions) |
| Employee-Related |
| |
Accrued restructuring action balances as of December 31, 2019 | $ | | ||
Cash payments |
| ( | ||
Adjustments | ( | |||
Accrued restructuring action balances as of June 30, 2020 | $ | | ||
Remaining activities related to this restructuring are expected to be completed largely through early 2021.
NOTE 6. Supplemental Income Statement Information
Other expense (income), net consists of the following:
| Three months ended |
| Six months ended | ||||||||||
June 30, | June 30, |
| |||||||||||
(Millions) | 2020 |
| 2019 |
| 2020 | 2019 | |||||||
Interest expense | $ | | $ | | $ | | $ | | |||||
Interest income |
| ( |
| ( |
| ( |
| ( | |||||
Pension and postretirement net periodic benefit cost (benefit) | ( | | ( | ( | |||||||||
Loss on deconsolidation of Venezuelan subsidiary |
| — |
| |
| — |
| | |||||
Total | $ | | $ | | $ | | $ | | |||||
Pension and postretirement net periodic benefit costs described in the table above include all components of defined benefit plan net periodic benefit costs except service cost, which is reported in various operating expense lines. Pension and postretirement net periodic benefit costs include a second quarter 2019 charge related to the voluntary early retirement incentive program announced in May 2019. Refer to Note 11 for additional details on the voluntary early retirement incentive program in addition to the components of pension and postretirement net periodic benefit costs.
In the second quarter of 2019, the Company incurred a charge of $
18
NOTE 7. Supplemental Equity and Comprehensive Income Information
Cash dividends declared and paid totaled $
Consolidated Changes in Equity
Three months ended June 30, 2020
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at March 31, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| ( | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| |
| |
| — | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| ( |
| ( |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Purchase of subsidiary shares | ( | ( | |||||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| — |
| — | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Six months ended June 30, 2020
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at December 31, 2019 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| ( | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| ( |
| ( |
| ( | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| |
| |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| ( | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Purchase of subsidiary shares | ( | ( | |||||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| ( |
| ( | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2020 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
19
Three months ended June 30, 2019
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at March 31, 2019 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Net income |
| |
| |
| | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| |
| |
| | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| ( |
| ( |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| ( |
| ( | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2019 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Six months ended June 30, 2019
3M Company Shareholders |
| ||||||||||||||||||
Common | Accumulated |
| |||||||||||||||||
Stock and | Other |
| |||||||||||||||||
Additional | Comprehensive | Non- |
| ||||||||||||||||
Paid-in | Retained | Treasury | Income | controlling |
| ||||||||||||||
(Millions) |
| Total |
| Capital |
| Earnings |
| Stock |
| (Loss) |
| Interest |
| ||||||
Balance at December 31, 2018 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
Impact of adoption of ASU No. 2018-02* | — | | ( | ||||||||||||||||
Impact of adoption of ASU No. 2016-02* | | | |||||||||||||||||
Net income |
| |
| |
| | |||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||
Cumulative translation adjustment |
| |
| |
| | |||||||||||||
Defined benefit pension and post-retirement plans adjustment |
| |
| |
| — | |||||||||||||
Cash flow hedging instruments |
| ( |
| ( |
| — | |||||||||||||
Total other comprehensive income (loss), net of tax |
| | |||||||||||||||||
Dividends declared |
| ( |
| ( | |||||||||||||||
Stock-based compensation |
| |
| | |||||||||||||||
Reacquired stock |
| ( |
| ( | |||||||||||||||
Issuances pursuant to stock option and benefit plans |
| |
| ( |
| | |||||||||||||
Balance at June 30, 2019 |
| $ | |
| $ | |
| $ | |
| $ | ( |
| $ | ( |
| $ | | |
*See Note 1 in 3M’s 2019 Annual Report on Form 10-K.
20
Changes in Accumulated Other Comprehensive Income (Loss) Attributable to 3M by Component
Three months ended June 30, 2020
|
|
|
| Total |
| ||||||||
Defined Benefit | Cash Flow | Accumulated |
| ||||||||||
Pension and | Hedging | Other |
| ||||||||||
Cumulative | Postretirement | Instruments, | Comprehensive |
| |||||||||
Translation | Plans | Unrealized | Income |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | (Loss) |
| ||||||||
Balance at March 31, 2020, net of tax: | $ | ( | $ | ( | $ | | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| |
| ( |
| ( |
| | |||||
Amounts reclassified out |
| — |
| |
| ( |
| | |||||
Total other comprehensive income (loss), before tax |
| |
| |
| ( |
| | |||||
Tax effect |
| |
| ( |
| |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| |
| |
| ( |
| | |||||
Balance at June 30, 2020, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Six months ended June 30, 2020
|
|
|
| Total |
| ||||||||
Defined Benefit | Cash Flow | Accumulated |
| ||||||||||
Pension and | Hedging | Other |
| ||||||||||
Cumulative | Postretirement | Instruments, | Comprehensive |
| |||||||||
Translation | Plans | Unrealized | Income |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | (Loss) |
| ||||||||
Balance at December 31, 2019, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| ( |
| ( |
| |
| ( | |||||
Amounts reclassified out |
| — |
| |
| ( |
| | |||||
Total other comprehensive income (loss), before tax |
| ( |
| |
| |
| ( | |||||
Tax effect |
| — |
| ( |
| ( |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| ( |
| |
| |
| ( | |||||
Balance at June 30, 2020, net of tax: | $ | ( | $ | ( | $ | ( | $ | ( | |||||
Three months ended June 30, 2019
|
|
|
| Total |
| ||||||||
Defined Benefit | Cash Flow | Accumulated |
| ||||||||||
Pension and | Hedging | Other |
| ||||||||||
Cumulative | Postretirement | Instruments, | Comprehensive |
| |||||||||
Translation | Plans | Unrealized | Income |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | (Loss) |
| ||||||||
Balance at March 31, 2019, net of tax: | $ | ( | $ | ( | $ | | $ | ( | |||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| ( |
| |
| ( |
| | |||||
Amounts reclassified out |
| |
| |
| ( |
| | |||||
Total other comprehensive income (loss), before tax |
| |
| |
| ( |
| | |||||
Tax effect |
| |
| ( |
| |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| |
| |
| ( |
| | |||||
Balance at June 30, 2019, net of tax: | $ | ( | $ | ( | $ | | $ | ( | |||||
21
Six months ended June 30, 2019
|
|
|
| Total |
| ||||||||
Defined Benefit | Cash Flow | Accumulated |
| ||||||||||
Pension and | Hedging | Other |
| ||||||||||
Cumulative | Postretirement | Instruments, | Comprehensive |
| |||||||||
Translation | Plans | Unrealized | Income |
| |||||||||
(Millions) | Adjustment | Adjustment | Gain (Loss) | (Loss) |
| ||||||||
Balance at December 31, 2018, net of tax: | $ | ( | $ | ( | $ | | $ | ( | |||||
Impact of adoption of ASU No. 2018-02* | ( | ( | ( | ( | |||||||||
Other comprehensive income (loss), before tax: | |||||||||||||
Amounts before reclassifications |
| |
| |
| ( |
| | |||||
Amounts reclassified out |
| |
| |
| ( |
| | |||||
Total other comprehensive income (loss), before tax |
| |
| |
| ( |
| | |||||
Tax effect |
| ( |
| ( |
| |
| ( | |||||
Total other comprehensive income (loss), net of tax |
| |
| |
| ( |
| | |||||
Balance at June 30, 2019, net of tax | $ | ( | $ | ( | $ | | $ | ( | |||||
*See Note 1 in 3M’s 2019 Annual Report on Form 10-K.
Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within cumulative translation does include impacts from items such as net investment hedge transactions. Reclassification adjustments are made to avoid double counting in comprehensive income items that are subsequently recorded as part of net income.
Reclassifications out of Accumulated Other Comprehensive Income Attributable to 3M
Amount Reclassified from |
| ||||||||||||||
Details about Accumulated Other | Accumulated Other Comprehensive Income | ||||||||||||||
Comprehensive Income Components | Three months ended June 30, | Six months ended June 30, | Location on Income |
| |||||||||||
(Millions) | 2020 |
| 2019 |
| 2020 |
| 2019 | Statement |
| ||||||
Cumulative translation adjustment | |||||||||||||||
Deconsolidation of Venezuelan subsidiary | $ | — | $ | ( | $ | — | $ | ( | Other income (expense), net | ||||||
Total before tax | — | ( | — | ( | |||||||||||
Tax effect | — | — | — | — | Provision for income taxes | ||||||||||
Net of tax | $ | — | $ | ( | $ | — | $ | ( | |||||||
Defined benefit pension and postretirement plans adjustments | |||||||||||||||
Gains (losses) associated with defined benefit pension and postretirement plans amortization | |||||||||||||||
Transition asset | $ | — | $ | — | $ | ( |
| $ | — |
| See Note 11 | ||||
Prior service benefit | | | $ | |
| $ | |
| See Note 11 | ||||||
Net actuarial loss | ( | ( | ( | ( | See Note 11 | ||||||||||
Curtailments/Settlements |
| ( |
| — |
| ( |
|
| — |
| See Note 11 | ||||
Deconsolidation of Venezuelan subsidiary | — | ( | — | ( | Other income (expense), net | ||||||||||
Total before tax |
| ( |
| ( |
| ( |
| ( | |||||||
Tax effect |
| |
| |
| |
|
| |
| Provision for income taxes | ||||
Net of tax | $ | ( | $ | ( | $ | ( | $ | ( | |||||||
Cash flow hedging instruments gains (losses) | |||||||||||||||
Foreign currency forward/option contracts | $ | | $ | | $ | |
| $ | |
| Cost of sales | ||||
Interest rate contracts |
| ( |
| ( |
| ( |
|
| ( |
| Interest expense | ||||
Total before tax |
| |
| |
| |
| | |||||||
Tax effect |
| ( |
| ( |
| ( |
|
| ( |
| Provision for income taxes | ||||
Net of tax | $ | | $ | | $ | | $ | | |||||||
Total reclassifications for the period, net of tax | $ | ( | $ | ( | $ | ( | $ | ( | |||||||
22
NOTE 8. Income Taxes
The Company is under IRS examination or appeals for the tax years 2015 through 2018. The IRS has completed its field examination of the U.S. federal income tax returns for all years through 2016, but the years have not closed as the Company is in the process of resolving issues identified during those examinations. In addition to the U.S. federal examination, there is also audit activity in several U.S. state and foreign jurisdictions. As of June 30, 2020, no taxing authority has proposed significant adjustments to the Company’s tax positions for which the Company is not adequately reserved.
It is reasonably possible that the amount of unrecognized tax benefits could significantly change within the next 12 months. At this time, the Company is not able to estimate the range by which these potential events could impact 3M’s unrecognized tax benefits in the next 12 months. The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of June 30, 2020 and December 31, 2019 are $
As of June 30, 2020 and December 31, 2019, the Company had valuation allowances of $
The effective tax rate for the second quarter of 2020 was
The effective tax rate for the first six months of 2020 was
In March 2020, in response to the impact of the COVID-19 pandemic in the US and across the globe, the United States Congress passed the Coronavirus Aid, Relief and Economic Security (CARES) Act. The enactment period impacts to 3M were immaterial to income tax expense.
NOTE 9. Marketable Securities and Held-to-Maturity Debt Securities
The Company invests in asset-backed securities, certificates of deposit/time deposits, commercial paper, and other securities. The following is a summary of amounts recorded on the Consolidated Balance Sheet for marketable securities (current and non-current).
(Millions) | June 30, 2020 | December 31, 2019 |
| ||||
Commercial paper | $ | | $ | | |||
Certificates of deposit/time deposits |
| |
| | |||
U.S. municipal securities |
| |
| | |||
Current marketable securities | $ | | $ | | |||
U.S. municipal securities | $ | | $ | | |||
Non-current marketable securities | $ | | $ | | |||
Total marketable securities | $ | | $ | | |||
23
At June 30, 2020 and December 31, 2019, gross unrealized, gross realized, and net realized gains and/or losses (pre-tax) were not material.
The balances at June 30, 2020 for marketable securities by contractual maturity are shown below. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(Millions) |
| June 30, 2020 |
| |
Due in one year or less | $ | | ||
Due after one year through five years |
| | ||
Due after five years through ten years |
| | ||
Total marketable securities | $ | | ||
Held-to-Maturity Debt Securities
In connection with the in-substance debt defeasance of the Third Lien Notes described in Note 10, the Company purchased a $
NOTE 10. Long-Term Debt and Short-Term Borrowings
In March 2020, 3M issued $
As of June 30, 2020, the Company had
3M has a credit facility expiring in July 2020 in the amount of
In November 2019, 3M entered into a credit facility expiring in November 2020 in the amount of
In conjunction with the October 2019 acquisition of Acelity (see Note 3), 3M assumed outstanding debt of the business, of which $
In May 2020, 3M repaid the aggregate $
24
Future Maturities of Long-term Debt
Maturities of long-term debt in the table below reflect the impact of put provisions associated with certain debt instruments and are net of the unaccreted debt issue costs such that total maturities equal the carrying value of long-term debt as of June 30, 2020. The maturities of long-term debt for the periods subsequent to June 30, 2020 are as follows (in millions):
Remainder of |
|
|
|
|
|
| After |
|
| ||||||||||||||
2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2025 | Total |
| |||||||||||||||
$ | | $ | | $ | | $ | | $ | | $ | | $ | | $ | | ||||||||
NOTE 11. Pension and Postretirement Benefit Plans
The service cost component of defined benefit net periodic benefit cost is recorded in cost of sales; selling, general and administrative expenses; and research, development and related expenses. The other components of net periodic benefit cost are reflected in other expense (income), net. Components of net periodic benefit cost and other supplemental information for the three and six months ended June 30, 2020 and 2019 follow:
Benefit Plan Information
Three months ended June 30, |
| ||||||||||||||||||
Qualified and Non-qualified |
| ||||||||||||||||||
Pension Benefits | Postretirement |
| |||||||||||||||||
United States | International | Benefits |
| ||||||||||||||||
(Millions) |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| ||||||
Net periodic benefit cost (benefit) | |||||||||||||||||||
Operating expense | |||||||||||||||||||
Service cost | $ | | $ | | $ | | $ | | $ | | $ | | |||||||
Non-operating expense | |||||||||||||||||||
Interest cost | $ | | $ | | $ | | $ | | $ | | $ | | |||||||
Expected return on plan assets |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | |||||||
Amortization of prior service benefit |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | |||||||
Amortization of net actuarial loss | | | | | | | |||||||||||||
Settlements, curtailments, special termination benefits and other |
| — |
| |
| — |
| |
| |
| — | |||||||
Total non-operating expense (benefit) | ( | | ( | ( | | | |||||||||||||
Total net periodic benefit cost (benefit) | $ | | $ | | $ | | $ | | $ | | $ | | |||||||
Six months ended June 30, |
| ||||||||||||||||||
Qualified and Non-qualified |
| ||||||||||||||||||
Pension Benefits | Postretirement |
| |||||||||||||||||
United States | International | Benefits |
| ||||||||||||||||
(Millions) |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| ||||||
Net periodic benefit cost (benefit) | |||||||||||||||||||
Operating expense | |||||||||||||||||||
Service cost | $ | | $ | | $ | | $ | | $ | | $ | | |||||||
Non-operating expense | |||||||||||||||||||
Interest cost | $ | | $ | | $ | | $ | | $ | | $ | | |||||||
Expected return on plan assets |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | |||||||
Amortization of transition asset |
| — |
| — |
| |
| — |
| — |
| — | |||||||
Amortization of prior service benefit |
| ( |
| ( |
| ( |
| ( |
| ( |
| ( | |||||||
Amortization of net actuarial loss | | | | | | | |||||||||||||
Settlements, curtailments, special termination benefits and other |
| — |
| |
| — |
| |
| |
| — | |||||||
Total non-operating expense (benefit) | ( | ( | ( | ( | | | |||||||||||||
Total net periodic benefit cost (benefit) | $ | | $ | | $ | | $ | | $ | | $ | | |||||||
For the six months ended June 30, 2020 contributions totaling $
25
pension contribution obligation for its U.S. plans in 2020. Future contributions will depend on market conditions, interest rates and other factors. 3M’s annual measurement date for pension and postretirement assets and liabilities is December 31 each year, which is also the date used for the related annual measurement assumptions.
In May 2019 (as part of the 2019 restructuring actions discussed in Note 5), the Company began offering a voluntary early retirement incentive program to certain eligible participants of its U.S. pension plans who meet age and years of pension service requirements. The eligible participants who accepted the offer and retired by July 1, 2019 received an enhanced pension benefit. Pension benefits were enhanced by adding
In May 2019, 3M modified the 3M Retiree Life Insurance Plan postretirement benefit to close it to new participants effective August 1, 2019 (which results in employees who retire on or after August 1, 2019 not being eligible to participate in the plan) and reducing the maximum life insurance and death benefit to $
In the second quarter of 2020, as a result of the divestiture of the drug delivery business, the Company recognized a curtailment in its United Kingdom Pension Plan. The resulting re-measurement of the pension plan funded status reduced long-term prepaid pension and post retirement assets (located within “other assets” of the Company’s balance sheet) by approximately $
NOTE 12. Derivatives
The Company uses interest rate swaps, currency swaps, commodity price swaps, and forward and option contracts to manage risks generally associated with foreign exchange rate, interest rate and commodity price fluctuations. The information that follows explains the various types of derivatives and financial instruments used by 3M, how and why 3M uses such instruments, how such instruments are accounted for, and how such instruments impact 3M’s financial position and performance.
Additional information with respect to derivatives is included elsewhere as follows:
| ● | Impact on other comprehensive income of nonderivative hedging and derivative instruments is included in Note 7. |
| ● | Fair value of derivative instruments is included in Note 13. |
| ● | Derivatives and/or hedging instruments associated with the Company’s long-term debt are described in Note 12 in 3M’s 2019 Annual Report on Form 10-K. |
Types of Derivatives/Hedging Instruments and Inclusion in Income/Other Comprehensive Income
Cash Flow Hedges:
For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period during which the hedged transaction affects earnings. Gains and losses on the derivative representing hedge components excluded from the assessment of effectiveness are recognized in current earnings.
Cash Flow Hedging - Foreign Currency Forward and Option Contracts: The Company enters into foreign exchange forward and option contracts to hedge against the effect of exchange rate fluctuations on cash flows denominated in foreign currencies. These transactions are designated as cash flow hedges. The settlement or extension of these derivatives will result in reclassifications (from accumulated other comprehensive income) to earnings in the period during which the hedged transactions affect earnings. 3M may dedesignate these cash flow hedge relationships in advance of the occurrence of the forecasted transaction. The portion of gains or losses on the derivative instrument previously included in accumulated other comprehensive income for dedesignated hedges remains in accumulated other comprehensive income until the forecasted transaction occurs or becomes probable of not occurring. Changes in the value of derivative instruments after dedesignation are recorded in earnings and are included in the Derivatives Not Designated as
26
Hedging Instruments section below. The maximum length of time over which 3M hedges its exposure to the variability in future cash flows of the forecasted transactions is
Cash Flow Hedging - Interest Rate Contracts: The Company may use forward starting interest rate swap or treasury rate lock contracts to hedge exposure to variability in cash flows from interest payments on forecasted debt issuances. Additional information regarding previously issued but terminated interest rate contracts, which have related balances within accumulated other comprehensive income being amortized over the underlying life of related debt, can be found in Note 14 in 3M’s 2019 Annual Report on Form 10-K.
In March 2020, the Company entered into treasury rate lock contracts with a notional amount of $
The amortization of gains and losses on forward starting interest rate swap and treasury rate lock contracts is included in the tables below as part of the gain/(loss) reclassified from accumulated other comprehensive income into income.
As of June 30, 2020, the Company had a balance of $
The location in the consolidated statements of income and comprehensive income and amounts of gains and losses related to derivative instruments designated as cash flow hedges are provided in the following table. Reclassifications of amounts from accumulated other comprehensive income into income include accumulated gains (losses) on dedesignated hedges at the time earnings are impacted by the forecasted transactions.
Pretax Gain (Loss) |
| ||||||||
Recognized in Other | Pretax Gain (Loss) Reclassified |
| |||||||
Comprehensive | from Accumulated Other |
| |||||||
Income on Derivative | Comprehensive Income into Income |
| |||||||
Three months ended June 30, 2020 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency forward/option contracts | $ | ( |
| Cost of sales | $ | | |||
Interest rate contracts |
| — |
| Interest expense |
| ( | |||
Total | $ | ( | $ | | |||||
Six months ended June 30, 2020 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency forward/option contracts | $ | |
| Cost of sales | $ | | |||
Interest rate contracts |
| ( |
| Interest expense |
| ( | |||
Total | $ | | $ | | |||||
Three months ended June 30, 2019 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency forward/option contracts | $ | |
| Cost of sales | $ | | |||
Interest rate contracts |
| ( |
| Interest expense |
| ( | |||
Total | $ | ( | $ | | |||||
Six months ended June 30, 2019 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency forward/option contracts | $ | |
| Cost of sales | $ | | |||
Interest rate contracts |
| ( |
| Interest expense |
| ( | |||
Total | $ | ( | $ | | |||||
27
Fair Value Hedges:
For derivative instruments that are designated and qualify as fair value hedges, the gain or loss on the derivatives as well as the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings.
Fair Value Hedging - Interest Rate Swaps: The Company manages interest expense using a mix of fixed and floating rate debt. To help manage borrowing costs, the Company may enter into interest rate swaps. Under these arrangements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. The mark-to-market of these fair value hedges is recorded as gains or losses in interest expense and is offset by the gain or loss of the underlying debt instrument, which also is recorded in interest expense. Additional information regarding designated interest rate swaps can be found in Note 14 in 3M’s 2019 Annual Report on Form 10-K.
Refer to the section below titled Statement of Income Location and Impact of Cash Flow and Fair Value Derivative Instruments for details on the location within the consolidated statements of income for amounts of gains and losses related to derivative instruments designated as fair value hedges and similar information relative to the hedged items for the three and six months ended June 30, 2020 and 2019.
The following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustments for fair value hedges:
Cumulative Amount of Fair Value Hedging |
| ||||||||||||
Carrying Value of the | Adjustment Included in the Carrying Value |
| |||||||||||
Hedged Liabilities (in millions) | of the Hedged Liabilities (in millions) |
| |||||||||||
Location on the Consolidated Balance Sheet |
| June 30, 2020 |
| December 31, 2019 |
| June 30, 2020 |
| December 31, 2019 |
| ||||
Short-term borrowings and current portion of long-term debt |
| $ | | $ | |
| $ | | $ | — | |||
Long-term debt | | | | | |||||||||
Total | $ | | $ | | $ | | $ | | |||||
Net Investment Hedges:
The Company may use non-derivative (foreign currency denominated debt) and derivative (foreign exchange forward contracts) instruments to hedge portions of the Company’s investment in foreign subsidiaries and manage foreign exchange risk. For instruments that are designated and qualify as hedges of net investments in foreign operations and that meet the effectiveness requirements, the net gains or losses attributable to changes in spot exchange rates are recorded in cumulative translation within other comprehensive income. Amounts excluded from the assessment of hedge effectiveness, including the time value of the forward contract at the inception of the hedge, are recognized in earnings using an amortization approach over the life of the hedging instrument on a straight-line basis. Any difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in cumulative translation within other comprehensive income. Recognition in earnings of amounts previously recorded in cumulative translation is limited to circumstances such as complete or substantially complete liquidation of the net investment in the hedged foreign operation. To the extent foreign currency denominated debt is not designated in or is dedesignated from a net investment hedge relationship, changes in value of that portion of foreign currency denominated debt due to exchange rate changes are recorded in earnings through their maturity date.
3M’s use of foreign exchange forward contracts designated in hedges of the Company’s net investment in foreign subsidiaries can vary by time period depending on when foreign currency denominated debt balances designated in such relationships are dedesignated, matured, or are newly issued and designated. Additionally, variation can occur in connection with the extent of the Company’s desired foreign exchange risk coverage.
At June 30, 2020, the total notional amount of foreign exchange forward contracts designated in net investment hedges was approximately
The location in the consolidated statements of income and comprehensive income and amounts of gains and losses related to derivative and nonderivative instruments designated as net investment hedges are as follows. There were
28
effective portion of net investment hedges out of accumulated other comprehensive income into income for the periods presented in the table below.
| |||||||||
Pretax Gain (Loss) |
| ||||||||
Recognized as |
| ||||||||
Cumulative Translation | Amount of Gain (Loss) Excluded |
| |||||||
within Other | from Effectiveness Testing |
| |||||||
Comprehensive Income | Recognized in Income |
| |||||||
Three months ended June 30, 2020 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency denominated debt | $ | ( |
| Cost of sales | $ | — | |||
Foreign currency forward contracts |
| |
| Cost of sales |
| — | |||
Total | $ | ( | $ | — | |||||
Six months ended June 30, 2020 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency denominated debt | $ | |
| Cost of sales | $ | — | |||
Foreign currency forward contracts |
| |
| Cost of sales |
| | |||
Total | $ | | $ | | |||||
Three months ended June 30, 2019 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency denominated debt | $ | ( |
| Cost of sales | $ | — | |||
Foreign currency forward contracts | ( | Cost of sales | | ||||||
Total | $ | ( | $ | | |||||
Six months ended June 30, 2019 (Millions) |
| Amount |
| Location |
| Amount |
| ||
Foreign currency denominated debt | $ | |
| Cost of sales | $ | — | |||
Foreign currency forward contracts | | Cost of sales | | ||||||
Total | $ | | $ | | |||||
Derivatives Not Designated as Hedging Instruments:
Derivatives not designated as hedging instruments include dedesignated foreign currency forward and option contracts that formerly were designated in cash flow hedging relationships (as referenced in the Cash Flow Hedges section above). In addition, 3M enters into foreign currency forward contracts to offset, in part, the impacts of certain intercompany activities and enters into commodity price swaps to offset, in part, fluctuations in costs associated with the use of certain commodities and precious metals. These derivative instruments are not designated in hedging relationships; therefore, fair value gains and losses on these contracts are recorded in earnings. The Company does not hold or issue derivative financial instruments for trading purposes.
The location in the consolidated statement of income and amounts of gains and losses related to derivative instruments not designated as hedging instruments are as follows:
Three months ended June 30, 2020 | Six months ended June 30, 2020 |
| ||||||||||
Gain (Loss) on Derivative Recognized in | Gain (Loss) on Derivative Recognized in |
| ||||||||||
Income | Income |
| ||||||||||
(Millions) |
| Location |
| Amount |
| Location |
| Amount |
| |||
Foreign currency forward/option contracts |
| Cost of sales | $ | ( |
| Cost of sales | $ | | ||||
Foreign currency forward contracts |
| Interest expense |
| ( |
| Interest expense |
| ( | ||||
Total | $ | ( | $ | ( | ||||||||
29
Three months ended June 30, 2019 | Six months ended June 30, 2019 | |||||||||||
Gain (Loss) on Derivative Recognized in | Gain (Loss) on Derivative Recognized in | |||||||||||
Income | Income | |||||||||||
(Millions) |
| Location |
| Amount |
| Location |
| Amount | ||||
Foreign currency forward/option contracts |
| Cost of sales | $ | — |
| Cost of sales | $ | ( | ||||
Foreign currency forward contracts |
| Interest expense |
| ( |
| Interest expense |
| ( | ||||
Total | $ | ( | $ | ( | ||||||||
Statement of Income Location and Impact of Cash Flow and Fair Value Derivative Instruments
The location in the consolidated statement of income and pre-tax amounts recognized in income related to derivative instruments designated in a cash flow or fair value hedging relationship are as follows:
Location and Amount of Gain (Loss) Recognized in Income | Location and Amount of Gain (Loss) Recognized in Income | ||||||||||||
Three months ended June 30, 2020 | Six months ended June 30, 2020 | ||||||||||||
(Millions) | Cost of sales | Other expense | Cost of sales | Other expense | |||||||||
Total amounts of income and expense line items presented in the consolidated statement of income in which the effects of cash flow or fair value hedges are recorded | $ | | $ | | $ | | $ | | |||||
The effects of cash flow and fair value hedging: | |||||||||||||
Gain or (loss) on cash flow hedging relationships: | |||||||||||||
Foreign currency forward/option contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | $ | | $ | — | $ | | $ | — | |||||
Interest rate contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | — | ( | — | ( | |||||||||
Gain or (loss) on fair value hedging relationships: | |||||||||||||
Interest rate contracts: | |||||||||||||
Hedged items | $ | — | $ | | $ | — | $ | — | |||||
Derivatives designated as hedging instruments | — | ( | — | — | |||||||||
Location and Amount of Gain (Loss) Recognized in Income | Location and Amount of Gain (Loss) Recognized in Income | ||||||||||||
Three months ended June 30, 2019 | Six months ended June 30, 2019 | ||||||||||||
(Millions) | Cost of sales | Other expense | Cost of sales | Other expense | |||||||||
Total amounts of income and expense line items presented in the consolidated statement of income in which the effects of cash flow or fair value hedges are recorded | $ | | $ | | $ | | $ | | |||||
The effects of cash flow and fair value hedging: | |||||||||||||
Gain or (loss) on cash flow hedging relationships: | |||||||||||||
Foreign currency forward/option contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | $ | | $ | — | $ | | $ | — | |||||
Interest rate contracts: | |||||||||||||
Amount of gain or (loss) reclassified from accumulated other comprehensive income into income | — | ( | — | ( | |||||||||
Gain or (loss) on fair value hedging relationships: | |||||||||||||
Interest rate contracts: | |||||||||||||
Hedged items | $ | — | $ | ( | $ | — | $ | ( | |||||
Derivatives designated as hedging instruments | — | | — | | |||||||||
30
Location and Fair Value Amount of Derivative Instruments
The following tables summarize the fair value of 3M’s derivative instruments, excluding nonderivative instruments used as hedging instruments, and their location in the consolidated balance sheet. Notional amounts below are presented at period end foreign exchange rates, except for certain interest rate swaps, which are presented using the inception date’s foreign exchange rate. Additional information with respect to the fair value of derivative instruments is included in Note 13.
Gross |
| Assets |
| Liabilities |
| |||||||||
Notional | Fair | Fair |
| |||||||||||
June 30, 2020 (Millions) | Amount | Location | Value Amount | Location | Value Amount |
| ||||||||
Derivatives designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Foreign currency forward/option contracts |
| |
| Other assets |
| |
| Other liabilities |
| | ||||
Interest rate contracts |
| |
| Other current assets |
| — |
| Other current liabilities |
| — | ||||
Interest rate contracts |
| |
| Other assets |
| |
| Other liabilities |
| — | ||||
Total derivatives designated as hedging instruments | $ | | $ | | ||||||||||
Derivatives not designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Total derivatives not designated as hedging instruments | $ | | $ | | ||||||||||
Total derivative instruments | $ | | $ | | ||||||||||
Gross |
| Assets |
| Liabilities |
| |||||||||
Notional | Fair | Fair |
| |||||||||||
December 31, 2019 (Millions) | Amount | Location | Value Amount | Location | Value Amount |
| ||||||||
Derivatives designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Foreign currency forward/option contracts | | Other assets | | Other liabilities | | |||||||||
Interest rate contracts |
| |
| Other current assets |
| — |
| Other current liabilities |
| — | ||||
Interest rate contracts |
| |
| Other assets |
| |
| Other liabilities |
| — | ||||
Total derivatives designated as hedging instruments | $ | | $ | | ||||||||||
Derivatives not designated as | ||||||||||||||
hedging instruments | ||||||||||||||
Foreign currency forward/option contracts | $ | |
| Other current assets | $ | |
| Other current liabilities | $ | | ||||
Total derivatives not designated as hedging instruments | $ | | $ | | ||||||||||
Total derivative instruments | $ | | $ | | ||||||||||
Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments
The Company is exposed to credit loss in the event of nonperformance by counterparties in interest rate swaps, currency swaps, commodity price swaps, and forward and option contracts. However, the Company’s risk is limited to the fair value of the instruments. The Company actively monitors its exposure to credit risk through the use of credit approvals and credit limits, and by selecting major international banks and financial institutions as counterparties. 3M enters into master netting arrangements with counterparties when possible to mitigate credit risk in derivative transactions. A master netting arrangement may allow each counterparty to net settle amounts owed between a 3M entity and the counterparty as a result of multiple, separate derivative transactions. As of June 30, 2020, 3M has International Swaps and Derivatives Association (ISDA) agreements with
31
covered by these agreements exceeds specified thresholds or if a counterparty’s credit rating has been downgraded to a predetermined rating). The Company does not anticipate nonperformance by any of these counterparties.
3M has elected to present the fair value of derivative assets and liabilities within the Company’s consolidated balance sheet on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. However, the following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of netting arrangements with each of the counterparties. For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period based on the 3M entity that is a party to the transactions. Derivatives not subject to master netting agreements are not eligible for net presentation. As of the applicable dates presented below,
Offsetting of Financial Assets under Master Netting Agreements with Derivative Counterparties
Gross Amounts not Offset in the |
| ||||||||||||
|
| Consolidated Balance Sheet that are Subject |
|
| |||||||||
Gross Amount of | to Master Netting Agreements |
| |||||||||||
Derivative Assets | Gross Amount of |
| |||||||||||
Presented in the | Eligible Offsetting | Cash |
| ||||||||||
Consolidated | Recognized | Collateral | Net Amount of |
| |||||||||
June 30, 2020 (Millions) | Balance Sheet | Derivative Liabilities | Received | Derivative Assets |
| ||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | |||||
Derivatives not subject to master netting agreements |
| — |
| — | |||||||||
Total | $ | | $ | | |||||||||
December 31, 2019 (Millions) | |||||||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | |||||
Derivatives not subject to master netting agreements |
| — |
| — | |||||||||
Total | $ | | $ | | |||||||||
Offsetting of Financial Liabilities under Master Netting Agreements with Derivative Counterparties
Gross Amounts not Offset in the |
| ||||||||||||
|
| Consolidated Balance Sheet that are Subject |
|
| |||||||||
Gross Amount of | to Master Netting Agreements |
| |||||||||||
Derivative Liabilities | Gross Amount of |
| |||||||||||
Presented in the | Eligible Offsetting | Cash | Net Amount of |
| |||||||||
Consolidated | Recognized | Collateral | Derivative |
| |||||||||
June 30, 2020 (Millions) | Balance Sheet | Derivative Assets | Pledged | Liabilities |
| ||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | |||||
Derivatives not subject to master netting agreements |
| — |
| — | |||||||||
Total | $ | | $ | | |||||||||
December 31, 2019 (Millions) |
| ||||||||||||
Derivatives subject to master netting agreements | $ | | $ | | $ | — | $ | | |||||
Derivatives not subject to master netting agreements |
| — |
| — | |||||||||
Total | $ | | $ | | |||||||||
Currency Effects
3M estimates that year-on-year foreign currency transaction effects, including hedging impacts, increased pre-tax income by approximately $
32
NOTE 13. Fair Value Measurements
3M follows ASC 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. The Company adopted ASU No. 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement, as of January 1, 2020. This ASU primarily amended the disclosures around Level 3 investments, of which the Company had an immaterial amount for all periods presented. Refer to Note 1 for additional details.
In addition to the information above, refer to Note 15 in 3M’s 2019 Annual Report on Form 10-K for a qualitative discussion of the assets and liabilities that are measured at fair value on a recurring and nonrecurring basis, a description of the valuation methodologies used by 3M, and categorization within the valuation framework of ASC 820.
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis.
Fair Value Measurements |
| ||||||||||||
Description | Fair Value at | Using Inputs Considered as |
| ||||||||||
(Millions) |
| June 30, 2020 |
| Level 1 |
| Level 2 |
| Level 3 |
| ||||
Assets: | |||||||||||||
Available-for-sale: | |||||||||||||
Marketable securities: | |||||||||||||
Commercial paper | $ | | $ | — | $ | | $ | — | |||||
Certificates of deposit/time deposits |
| |
| — |
| |
| — | |||||
U.S. municipal securities |
| |
| — |
| |
| | |||||
Investments | | | — | — | |||||||||
Derivative instruments — assets: | |||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | |||||
Interest rate contracts |
| |
| — |
| |
| — | |||||
Liabilities: | |||||||||||||
Derivative instruments — liabilities: | |||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | |||||
Fair Value Measurements |
| ||||||||||||
Description | Fair Value at | Using Inputs Considered as |
| ||||||||||
(Millions) |
| December 31, 2019 |
| Level 1 |
| Level 2 |
| Level 3 |
| ||||
Assets: | |||||||||||||
Available-for-sale: | |||||||||||||
Marketable securities: | |||||||||||||
Commercial paper | $ | | $ | — | $ | | $ | — | |||||
Certificates of deposit/time deposits |
| |
| — |
| |
| — | |||||
U.S. municipal securities |
| |
| — |
| — |
| | |||||
Investments | | | — | — | |||||||||
Derivative instruments — assets: | |||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | |||||
Interest rate contracts |
| |
| — |
| |
| — | |||||
Liabilities: | |||||||||||||
Derivative instruments — liabilities: | |||||||||||||
Foreign currency forward/option contracts |
| |
| — |
| |
| — | |||||
33
The following table provides a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis in the table above that used significant unobservable inputs (level 3).
| Three months ended |
| Six months ended |
| |||||||||
Marketable securities — certain U.S. municipal securities only | June 30, | June 30, |
| ||||||||||
(Millions) | 2020 |
| 2019 | 2020 |
| 2019 |
| ||||||
Beginning balance | $ | | $ | | $ | | $ | | |||||
Total gains or losses: | |||||||||||||
Included in earnings |
| |
| |
| |
| | |||||
Included in other comprehensive income |
| |
| |
| |
| | |||||
Purchases and issuances |
| |
| |
| |
| | |||||
Sales and settlements |
| |
| |
| ( |
| | |||||
Transfers in and/or out of level 3 |
| |
| |
| |
| | |||||
Ending balance | $ | | $ | | $ | | $ | | |||||
Change in unrealized gains or losses for the period included in earnings for securities held at the end of the reporting period |
| — |
| — |
| — |
| — | |||||
In addition, the plan assets of 3M’s pension and postretirement benefit plans are measured at fair value on a recurring basis (at least annually). Refer to Note 13 in 3M’s 2019 Annual Report on Form 10-K.
Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis:
Disclosures are required for certain assets and liabilities that are measured at fair value, but are recognized and disclosed at fair value on a nonrecurring basis in periods subsequent to initial recognition. For 3M, such measurements of fair value relate primarily to indefinite-lived and long-lived asset impairments, goodwill impairments, and adjustment in carrying value of equity securities for which the measurement alternative of cost less impairment plus or minus observable price changes is used. 3M reflected an immaterial charge related to impairment of certain indefinite-lived assets and a net charge of $
Fair Value of Financial Instruments:
The Company’s financial instruments include cash and cash equivalents, marketable securities, held-to-maturity debt securities, accounts receivable, certain investments, accounts payable, borrowings, and derivative contracts. The fair values of cash equivalents, accounts receivable, held-to-maturity debt securities, accounts payable, and short-term borrowings and current portion of long-term debt approximated carrying values because of the short-term nature of these instruments. Available-for-sale marketable securities, in addition to certain derivative instruments, are recorded at fair values as indicated in the preceding disclosures. To estimate fair values (classified as level 2) for its long-term debt, the Company utilized third-party quotes, which are derived all or in part from model prices, external sources, market prices, or the third-party’s internal records. Information with respect to the carrying amounts and estimated fair values of these financial instruments follow:
June 30, 2020 | December 31, 2019 |
| |||||||||||
| Carrying |
| Fair |
| Carrying |
| Fair |
| |||||
(Millions) | Value | Value | Value | Value |
| ||||||||
Long-term debt, excluding current portion | $ | | $ | | $ | | $ | | |||||
The fair values reflected above consider the terms of the related debt absent the impacts of derivative/hedging activity. The carrying amount of long-term debt referenced above is impacted by certain fixed-to-floating interest rate swaps that are designated as fair value hedges and by the designation of certain fixed rate Eurobond securities issued by the Company as hedging instruments of the Company’s net investment in its European subsidiaries. A number of 3M’s fixed-rate bonds were trading at a premium at June 30, 2020 and December 31, 2019 due to lower interest rates compared to issuance levels.
34
NOTE 14. Commitments and Contingencies
Legal Proceedings:
The Company and some of its subsidiaries are involved in numerous claims and lawsuits, principally in the United States, and regulatory proceedings worldwide. These claims, lawsuits and proceedings include, but are not limited to, products liability (involving products that the Company now or formerly manufactured and sold), intellectual property, commercial, antitrust, federal False Claims Act, securities, and state and federal environmental laws. Unless otherwise stated, the Company is vigorously defending all such litigation and proceedings. From time to time, the Company also receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can also lead to the assertion of claims or the commencement of administrative, civil or criminal legal proceedings against the Company and others, as well as to settlements. The outcomes of legal proceedings and regulatory matters are often difficult to predict. Any determination that the Company’s operations or activities are not, or were not, in compliance with applicable laws or regulations could result in the imposition of fines, civil or criminal penalties, and equitable remedies, including disgorgement, suspension or debarment or injunctive relief. Additional information about the Company’s process for disclosure and recording of liabilities and insurance receivables related to legal proceedings can be found in Note 16 “Commitments and Contingencies” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The following sections first describe the significant legal proceedings in which the Company is involved, and then describe the liabilities and associated insurance receivables the Company has accrued relating to its significant legal proceedings.
Respirator Mask/Asbestos Litigation
As of June 30, 2020, the Company is a named defendant, with multiple co-defendants, in numerous lawsuits in various courts that purport to represent approximately
The vast majority of the lawsuits and claims resolved by and currently pending against the Company allege use of some of the Company’s mask and respirator products and seek damages from the Company and other defendants for alleged personal injury from workplace exposures to asbestos, silica, coal mine dust or other occupational dusts found in products manufactured by other defendants or generally in the workplace. A minority of the lawsuits and claims resolved by and currently pending against the Company generally allege personal injury from occupational exposure to asbestos from products previously manufactured by the Company, which are often unspecified, as well as products manufactured by other defendants, or occasionally at Company premises.
The Company’s current volume of new and pending matters is substantially lower than it experienced at the peak of filings in 2003. The Company expects that filing of claims by unimpaired claimants in the future will continue to be at much lower levels than in the past. Accordingly, the number of claims alleging more serious injuries, including mesothelioma, other malignancies, and black lung disease, will represent a greater percentage of total claims than in the past. Over the past plus years, the Company has prevailed in
The Company has demonstrated in these past trial proceedings that its respiratory protection products are effective as claimed when used in the intended manner and in the intended circumstances. Consequently, the Company believes that claimants are unable to establish that their medical conditions, even if significant, are attributable to the Company’s respiratory protection products. Nonetheless, the Company’s litigation experience indicates that claims of persons alleging more serious injuries, including mesothelioma, other malignancies, and black lung disease, are costlier to resolve than the claims of unimpaired persons, and it
35
therefore believes the average cost of resolving pending and future claims on a per-claim basis will continue to be higher than it experienced in prior periods when the vast majority of claims were asserted by medically unimpaired claimants.
As previously reported, the State of West Virginia, through its Attorney General, filed a complaint in 2003 against the Company and
Respirator Mask/Asbestos Liabilities and Insurance Receivables
The Company regularly conducts a comprehensive legal review of its respirator mask/asbestos liabilities. The Company reviews recent and historical claims data, including without limitation, (i) the number of pending claims filed against the Company, (ii) the nature and mix of those claims (i.e., the proportion of claims asserting usage of the Company’s mask or respirator products and alleging exposure to each of asbestos, silica, coal or other occupational dusts, and claims pleading use of asbestos-containing products allegedly manufactured by the Company), (iii) the costs to defend and resolve pending claims, and (iv) trends in filing rates and in costs to defend and resolve claims, (collectively, the “Claims Data”). As part of its comprehensive legal review, the Company regularly provides the Claims Data to a third party with expertise in determining the impact of Claims Data on future filing trends and costs. The third party assists the Company in estimating the costs to defend and resolve pending and future claims. The Company uses these estimates to develop its best estimate of probable liability.
Developments may occur that could affect the Company’s estimate of its liabilities. These developments include, but are not limited to, significant changes in (i) the key assumptions underlying the Company’s accrual, including, the number of future claims, the nature and mix of those claims, the average cost of defending and resolving claims, and in maintaining trial readiness (ii) trial and appellate outcomes, (iii) the law and procedure applicable to these claims, and (iv) the financial viability of other co-defendants and insurers.
As a result of its review of its respirator mask/asbestos liabilities, of pending and expected lawsuits and of the cost of resolving claims of persons who claim more serious injuries, including mesothelioma, other malignancies, and black lung disease, the Company increased its accruals in the first six months of 2020 for respirator mask/asbestos liabilities by $
As of June 30, 2020, the Company’s receivable for insurance recoveries related to the respirator mask/asbestos litigation was $
36
Respirator Mask/Asbestos Litigation — Aearo Technologies
On April 1, 2008, a subsidiary of the Company acquired the stock of Aearo Holding Corp., the parent of Aearo Technologies (“Aearo”). Aearo manufactured and sold various products, including personal protection equipment, such as eye, ear, head, face, fall and certain respiratory protection products.
As of June 30, 2020, Aearo and/or other companies that previously owned and operated Aearo’s respirator business (American Optical Corporation, Warner-Lambert LLC, AO Corp. and Cabot Corporation (“Cabot”)) are named defendants, with multiple co-defendants, including the Company, in numerous lawsuits in various courts in which plaintiffs allege use of mask and respirator products and seek damages from Aearo and other defendants for alleged personal injury from workplace exposures to asbestos, silica-related, coal mine dust, or other occupational dusts found in products manufactured by other defendants or generally in the workplace.
As of June 30, 2020, the Company, through its Aearo subsidiary, had accruals of $
Aearo’s share of the contingent liability is further limited by an agreement entered into between Aearo and Cabot on July 11, 1995. This agreement provides that, so long as Aearo pays to Cabot a quarterly fee of $
Developments may occur that could affect the estimate of Aearo’s liabilities. These developments include, but are not limited to: (i) significant changes in the number of future claims, (ii) significant changes in the average cost of resolving claims, (iii) significant changes in the legal costs of defending these claims, (iv) significant changes in the mix and nature of claims received, (v) trial and appellate outcomes, (vi) significant changes in the law and procedure applicable to these claims, (vii) significant changes in the liability allocation among the co-defendants, (viii) the financial viability of members of the Payor Group including exhaustion of available insurance coverage limits, and/or (ix) a determination that the interpretation of the contractual obligations on which Aearo has estimated its share of liability is inaccurate. The Company cannot determine the impact of these potential developments on its current estimate of Aearo’s share of liability for these existing and future claims. If any of the developments described above were to occur, the actual amount of these liabilities for existing and future claims could be significantly larger than the amount accrued.
Because of the inherent difficulty in projecting the number of claims that have not yet been asserted, the complexity of allocating responsibility for future claims among the Payor Group, and the several possible developments that may occur that could affect the estimate of Aearo’s liabilities, the Company cannot estimate the amount or range of amounts by which Aearo’s liability may exceed the accrual the Company has established.
Environmental Matters and Litigation
The Company’s operations are subject to environmental laws and regulations including those pertaining to air emissions, wastewater discharges, toxic substances, and the handling and disposal of solid and hazardous wastes enforceable by national, state, and local
37
authorities around the world, and private parties in the United States and abroad. These laws and regulations provide, under certain circumstances, a basis for the remediation of contamination, for capital investment in pollution control equipment, for restoration of or compensation for damages to natural resources, and for personal injury and property damage claims. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations, defending personal injury and property damage claims, and modifying its business operations in light of its environmental responsibilities. In its effort to satisfy its environmental responsibilities and comply with environmental laws and regulations, the Company has established, and periodically updates, policies relating to environmental standards of performance for its operations worldwide.
Under certain environmental laws, including the United States Comprehensive Environmental Response, Compensation and Liability Act of 1980 (CERCLA) and similar state laws, the Company may be jointly and severally liable, typically with other companies, for the costs of remediation of environmental contamination at current or former facilities and at off-site locations. The Company has identified numerous locations, most of which are in the United States, at which it may have some liability. Please refer to the section entitled “Environmental Liabilities and Insurance Receivables” that follows for information on the amount of the accrual for such liabilities.
Environmental Matters
As previously reported, the Company has been voluntarily cooperating with ongoing reviews by local, state, federal (primarily the U.S. Environmental Protection Agency (EPA)), and international agencies of possible environmental and health effects of various perfluorinated compounds, including perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), or other per- and polyfluoroalkyl substances (collectively PFAS). As a result of its phase-out decision in May 2000, the Company no longer manufactures certain PFAS compounds including PFOA, PFOS, PFHxS, and their pre-cursor compounds. The Company ceased manufacturing and using the vast majority of these compounds within approximately
Regulatory activities concerning PFAS continue in the United States, Europe and elsewhere, and before certain international bodies. These activities include gathering of exposure and use information, risk assessment, and consideration of regulatory approaches. As the database of studies of both PFOA and PFOS has expanded, the EPA has developed human health effects documents summarizing the available data from these studies. In February 2014, the EPA initiated external peer review of its draft human health effects documents for PFOA and PFOS. The peer review panel met in August 2014. In May 2016, the EPA announced lifetime health advisory levels for PFOA and PFOS at
The Company is continuing to make progress in its work, under the supervision of state regulators, to remediate historic disposal of PFAS-containing waste associated with manufacturing operations at its Decatur, Alabama; Cottage Grove, Minnesota; and Cordova, Illinois plants. As previously reported, the Company entered into a voluntary remedial action agreement with the Alabama Department of Environmental Management (ADEM) to remediate the presence of PFAS in the soil and groundwater at the Company’s
38
manufacturing facility in Decatur, Alabama associated with the historic (1978-1998) incorporation of wastewater treatment plant sludge. With ADEM’s agreement, 3M is installing a multilayer cap on the former sludge incorporation areas and implementing groundwater migration controls and treatment.
The Company continues to work with the Minnesota Pollution Control Agency (MPCA) pursuant to the terms of the previously disclosed May 2007 Settlement Agreement and Consent Order to address the presence of certain PFAS in the soil and groundwater at former disposal sites in Washington County, Minnesota (Oakdale and Woodbury) and at the Company’s manufacturing facility at Cottage Grove, Minnesota. Under this agreement, the Company’s principal obligations include (i) evaluating releases of certain PFAS from these sites and proposing response actions; (ii) providing treatment or alternative drinking water upon identifying any level exceeding a Health Based Value (HBV) or Health Risk Limit (HRL) (i.e., the amount of a chemical in drinking water determined by the Minnesota Department of Health (MDH) to be safe for human consumption over a lifetime) for certain PFAS for which a HBV and/or HRL exists as a result of contamination from these sites; (iii) remediating identified sources of other PFAS at these sites that are not controlled by actions to remediate PFOA and PFOS; and (iv) sharing information with the MPCA about certain perfluorinated compounds. During 2008, the MPCA issued formal decisions adopting remedial options for the former disposal sites in Washington County, Minnesota (Oakdale and Woodbury). In August 2009, the MPCA issued a formal decision adopting remedial options for the Company’s Cottage Grove manufacturing facility. During the spring and summer of 2010, 3M began implementing the agreed upon remedial options at the Cottage Grove and Woodbury sites. 3M commenced the remedial option at the Oakdale site in late 2010. At each location the remedial options were recommended by the Company and approved by the MPCA. Remediation work has been completed at the Oakdale and Woodbury sites, and they are in an operational maintenance mode. Remediation work has been substantially completed at the Cottage Grove site, with operational and maintenance activities ongoing.
In August 2014, the Illinois EPA approved a request by the Company to establish a groundwater management zone at its manufacturing facility in Cordova, Illinois, which includes ongoing pumping of impacted site groundwater, groundwater monitoring and routine reporting of results.
In May 2017, the MDH issued new HBVs for PFOA and PFOS. The new HBVs are
In May 2018, the EPA announced a four-step PFAS action plan, which includes evaluating the need to set Safe Drinking Water Act maximum contaminant levels (MCLs) for PFOA and PFOS and beginning the steps necessary to designate PFOA and PFOS as “hazardous substances” under CERCLA. In November 2018, the EPA asked for public comment on draft toxicity assessments for
EPA announced in its Spring 2020 Regulatory Agenda, released in June 2020, that it intends to publish a notice of proposed rulemaking to designate PFOA and PFOS as hazardous substances under CERCLA in August 2020.
The U.S. Agency for Toxic Substances and Disease Registry (ATSDR) within the Department of Health and Human Services released a draft Toxicological Profile for PFAS for public review and comment in June 2018. In the draft report, ATSDR proposed draft minimal risk levels (MRLs) for PFOS, PFOA and several other PFAS. An MRL is an estimate of the daily human exposure to a
39
hazardous substance that is likely to be without appreciable risk of adverse non-cancer health effects over a specified duration of exposure. MRLs are not intended to define cleanup or action levels for ATSDR or other agencies. In August 2018, 3M submitted comments on the ATSDR proposal, noting that there are major shortcomings with the current draft, especially with the MRLs, and that the ATSDR’s profile must reflect the best science and full weight of evidence known about these chemicals.
Several state legislatures and state agencies have been evaluating or have taken actions related to cleanup standards, groundwater values or drinking water values for PFOS, PFOA, and other PFAS, and 3M has submitted various responsive comments. In September 2019, 3M and several other parties filed a lawsuit in New Hampshire state court to enjoin new PFAS regulations in New Hampshire. In November 2019, the court issued a preliminary injunction preventing the regulations from being enforced. In April 2020, the New Hampshire Supreme Court agreed to review several issues related to the preliminary injunctive order. In July 2020, the governor signed a bill passed by the New Hampshire legislature setting the same drinking water standards that had been enjoined by the court.
Vermont finalized drinking water standards for a combination of PFOA, PFOS and three other PFAS in March 2020. New Jersey finalized drinking water standards and designated PFOA and PFOS as hazardous substances in June 2020. Some other states have also been evaluating or have taken actions relating to PFOA, PFOS and other PFAS in products such as food packaging, carpets and other products.
The Company cannot predict what additional regulatory actions arising from the foregoing or other proceedings and activities, if any, may be taken regarding such compounds or the consequences of any such actions.
Litigation Related to Historical PFAS Manufacturing Operations in Alabama
As previously reported, a former employee filed a putative class action lawsuit against 3M, BFI Waste Management Systems of Alabama, and others in the Circuit Court of Morgan County, Alabama (the “St. John” case), seeking property damage from exposure to certain perfluorochemicals at or near the Company’s Decatur, Alabama, manufacturing facility. The parties have agreed to continue to stay the St. John case through September 2020, pending ongoing mediation between the parties involved in this case and another case discussed below.
In October 2015, West Morgan-East Lawrence Water & Sewer Authority (Water Authority) filed an individual complaint against 3M Company, Dyneon, L.L.C, and Daikin America, Inc., in the U.S. District Court for the Northern District of Alabama. The complaint also includes representative plaintiffs who brought the complaint on behalf of themselves, and a class of all owners and possessors of property who use water provided by the Water Authority and
In June 2016, the Tennessee Riverkeeper, Inc. (Riverkeeper), a non-profit corporation, filed a lawsuit in the U.S. District Court for the Northern District of Alabama against 3M; BFI Waste Systems of Alabama; the City of Decatur, Alabama; and the Municipal Utilities Board of Decatur, Morgan County, Alabama. The complaint alleges that the defendants violated the Resource Conservation and Recovery Act in connection with the disposal of certain PFAS through their ownership and operation of their respective sites. The complaint further alleges such practices may present an imminent and substantial endangerment to health and/or the environment and that Riverkeeper has suffered and will continue to suffer irreparable harm caused by defendants’ failure to abate the endangerment unless the court grants the requested relief, including declaratory and injunctive relief. This case has been stayed through August 2020, pending ongoing mediation between the parties in conjunction with the St. John case.
40
In August 2016, a group of over
In January 2017, several hundred plaintiffs sued 3M, Dyneon and Daikin America in Lawrence and Morgan Counties, Alabama (the “Owens” case). The plaintiffs are owners of property, residents, and holders of property interests who receive their water from the West Morgan-East Lawrence Water and Sewer Authority (Water Authority). They assert common law claims for negligence, nuisance, trespass, wantonness and battery, and they seek injunctive relief and punitive damages. The plaintiffs contend that the defendants own and operate manufacturing and disposal facilities in Decatur that have released and continue to release PFOA, PFOS and related chemicals into the groundwater and surface water of their sites, resulting in discharges into the Tennessee River. The plaintiffs contend that, as a result of the alleged discharges, the water supplied by the Water Authority to the plaintiffs was, and is, contaminated with PFOA, PFOS and related chemicals at a level dangerous to humans. The court denied a motion by co-defendant Daikin to stay this case pending resolution of the St. John case, and the case is progressing through discovery.
In November 2017, a putative class action (the “King” case) was filed against 3M, Dyneon, Daikin America and the West Morgan-East Lawrence Water and Sewer Authority (Water Authority) in the U.S. District Court for the Northern District of Alabama. The plaintiffs are residents of Lawrence and Morgan County, Alabama who receive their water from the Water Authority and seek injunctive relief, attorneys’ fees, compensatory and punitive damages for their alleged personal injuries. The plaintiffs contend that the defendants own and operate manufacturing and disposal facilities in Decatur, Alabama that have released and continue to release PFOA, PFOS and related chemicals into the groundwater and surface water of their sites, resulting in discharges into the Tennessee River. The plaintiffs contend that, as a result of the alleged discharges, the water supplied by the Water Authority to the plaintiffs was, and is, contaminated with PFOA, PFOS and related chemicals at a level dangerous to humans. In November 2019, the King plaintiffs amended their complaint to withdraw all class allegations, dismiss the Water Authority as a defendant and add
In July 2019, 3M announced that it had initiated an investigation into the possible presence of PFAS in
Litigation Related to Historical PFAS Manufacturing Operations in Minnesota
In July 2016, the City of Lake Elmo filed a lawsuit in the U.S. District Court for the District of Minnesota against 3M alleging that the City suffered damages from drinking water supplies contaminated with PFAS, including costs to construct alternative sources of drinking water. In April 2019, 3M and the City of Lake Elmo agreed to settle the lawsuit for less than $
State Attorneys General Litigation related to PFAS
Minnesota. In December 2010, the State of Minnesota, by its Attorney General, filed a lawsuit in Hennepin County District Court against 3M seeking damages and injunctive relief with respect to the presence of PFAS in the groundwater, surface water, fish or other aquatic life, and sediments in the state of Minnesota (the “NRD Lawsuit”). In February 2018, 3M and the State of Minnesota reached a resolution of the NRD Lawsuit. Under the terms of the settlement, 3M agreed to provide an $
New York. The State of New York, by its Attorney General, has filed
41
allegedly caused by Aqueous Film Forming Foam (AFFF) manufactured by 3M and others. Each of the
Ohio. In December 2018, the State of Ohio, by its Attorney General, filed a lawsuit in the Common Pleas Court of Lucas County, Ohio against 3M, Tyco Fire Products LP, Chemguard, Inc., Buckeye Fire Equipment Co., National Foam, Inc., and Angus Fire Armour Corp., seeking injunctive relief and compensatory and punitive damages for remediation costs and alleged injury to Ohio natural resources from AFFF manufacturers. This case was removed to federal court and transferred to the MDL.
New Jersey. In March 2019, the New Jersey Attorney General filed
In May 2019, the New Jersey Attorney General and NJDEP filed a lawsuit against 3M, DuPont, and
New Hampshire. In May 2019, the New Hampshire Attorney General filed
Vermont. In June 2019, the Vermont Attorney General filed
Michigan. In May 2019, the Michigan Attorney General issued a request for proposal seeking outside legal expertise in pursuing claims against manufacturers, distributors, and other parties related to PFAS. In January 2020, the Michigan Attorney General filed a lawsuit in state court against 3M, Dyneon, DuPont, Chemours and others seeking injunctive and equitable relief and damages for alleged injury to Michigan public natural resources and its residents relating to PFAS. The defendants filed a motion to dismiss in May 2020.
Guam. In September 2019, the Attorney General of Guam filed a lawsuit against 3M and other defendants relating to contamination of the territory’s drinking water supplies and other natural resources by PFAS, allegedly resulting from the use of AFFF products at several sites around the island. This lawsuit has been removed to federal court and transferred to the AFFF MDL.
Commonwealth of Northern Mariana Islands. In December 2019, the Attorney General of the Commonwealth of Northern Mariana Islands, a U.S. territory, filed a lawsuit against 3M and other defendants relating to contamination of the territory’s drinking water
42
supplies and other natural resources by PFAS, allegedly resulting from the use of AFFF products. This lawsuit has been removed to federal court and transferred to the AFFF MDL.
In addition to the above state attorneys general actions, the Company is in discussions with several other state attorneys general and agencies and responding to information and other requests relating to PFAS matters.
Aqueous Film Forming Foam (AFFF) Environmental Litigation
3M manufactured and marketed AFFF for use in firefighting at airports and military bases from approximately 1963 to 2002. As of June 30, 2020,
In December 2018, the U.S. Judicial Panel on Multidistrict Litigation (JPML) granted motions to transfer and consolidate all AFFF cases pending in federal courts to the U.S. District Court for the District of South Carolina to be managed in an MDL proceeding to centralize pre-trial proceedings. Additional AFFF cases continue to be transferred into the MDL as they are filed or removed to federal court. As of June 30, 2020, there were
In June 2019, several subsidiaries of Valero Energy Corporation, an independent petroleum refiner, filed
As of June 30, 2020, the Company was named but not served in
Other PFAS-related Product and Environmental Litigation
3M manufactured and sold products containing various PFOA and PFOS, including Scotchgard, for several decades. Starting in 2017, 3M has been served with individual and putative class action complaints in various state and federal courts alleging, among other things, that 3M’s customers’ improper disposal of PFOA and PFOS resulted in the contamination of groundwater or surface water. The plaintiffs in these cases generally allege that 3M failed to warn its customers about the hazards of improper disposal of the product. They also generally allege that contaminated groundwater has caused various injuries, including personal injury, loss of use and enjoyment of their properties, diminished property values, investigation costs, and remediation costs. Several companies have been sued along with 3M, including Saint-Gobain Performance Plastics Corp., Honeywell International Inc. f/k/a Allied-Signal Inc. and/or AlliedSignal Laminate Systems, Inc., Wolverine World Wide Inc., Georgia-Pacific LLC, E.I. DuPont De Nemours and Co., Chemours Co., and various carpet manufacturers.
43
In New York, 3M is defending
In Michigan,
Wolverine also filed a third-party complaint against 3M in a suit by the State of Michigan and intervenor townships that seeks to compel Wolverine to investigate and address contamination associated with its historic disposal activity. 3M filed an answer and counterclaims to Wolverine’s third-party complaint in June 2019. In September and October 2019, the parties (including 3M as third-party defendant) engaged in mediation. In December 2019, the State of Michigan, the intervening townships, and Wolverine announced that they had tentatively resolved the State and townships’ claims against Wolverine in exchange for a $
3M is also a defendant, together with Georgia-Pacific as co-defendant, in a putative class action in federal court in Michigan brought by residents of Parchment, who allege that the municipal drinking water is contaminated from waste generated by a paper mill owned by Georgia-Pacific’s corporate predecessor. The defendants have moved to dismiss certain claims in the complaint, and the parties have begun discovery on the remaining claims.
In Alabama and Georgia, 3M is defending
44
subscribers. This case has been removed to federal court where it remains in the early stages of litigation. 3M filed a motion to dismiss the putative class action in April 2020, which remains pending.
In Delaware, 3M is defending
In New Jersey, 3M is defending an action brought in federal court by Middlesex Water Company, alleging PFAS contamination of its water wells. 3M’s motion to transfer the case to the AFFF MDL was denied. 3M has moved to dismiss the complaint, and the case is currently in the early stages of discovery. In addition, 3M is defending a case brought in state court by multiple individuals with private drinking water wells near Dupont and Solvay facilities that were allegedly supplied with PFAS by 3M. Plaintiffs seek medical monitoring and damages. This case has been removed to federal court, where it remains in early stages.
In October 2018, 3M and other defendants, including DuPont and Chemours, were named in a putative class action in the U.S. District Court for the Southern District of Ohio brought by the named plaintiff, a firefighter allegedly exposed to PFAS chemicals through his use of firefighting foam, purporting to represent a putative class of all U.S. individuals with detectable levels of PFAS in their blood. The plaintiff brings claims for negligence, battery, and conspiracy and seeks injunctive relief, including an order “establishing an independent panel of scientists” to evaluate PFAS. 3M and other entities jointly filed a motion to dismiss in February 2019. In September 2019, the court denied the defendants’ motion to dismiss. In February 2020, the court denied 3M’s motion to transfer the case to the AFFF MDL. The case is in early stages of litigation.
Other PFAS-related Matters
In July 2019, the Company received a written request from the Subcommittee on Environment of the Committee on Oversight and Reform, U.S. House of Representatives, seeking certain documents and information relating to the Company’s manufacturing and distribution of PFAS products. In September 2019, a 3M representative testified before and responded to questions from the Subcommittee on Environment with respect to PFAS and the Company’s environmental stewardship initiatives. The Company continues to cooperate with the Subcommittee.
The Company operates under a 2009 consent order issued under the federal Toxic Substances Control Act (TSCA) (the “2009 TSCA consent order”) for the manufacture and use of
The Company is authorized to discharge wastewater from its Decatur plant pursuant to the terms of a Clean Water Act National Pollutant Discharge Elimination System (NPDES) permit issued by ADEM. The NPDES permit requires the Company to report on a monthly and quarterly basis the quality and quantity of pollutants discharged to the Tennessee River. In June 2019, the Company voluntarily disclosed to the EPA and ADEM that it had included incorrect values in certain of its monthly and quarterly reports. The Company has submitted the corrected values to both the EPA and ADEM.
As part of ongoing work with the EPA and ADEM to address compliance matters at the Decatur facility, the Company discovered it had not fully characterized its PFAS discharge in its NPDES permit. In September 2019, the Company disclosed the matter to the EPA and ADEM and announced that it had elected to temporarily idle certain other manufacturing processes at 3M Decatur. The Company is reviewing its operations at the plant, has installed wastewater treatment controls and has restarted idled processes.
45
As a result of the Company’s discussions with ADEM to address these and other related matters in the state of Alabama, 3M and ADEM have agreed to the terms of an interim Consent Order in July 2020 to cover all PFAS-related wastewater discharges and air emissions from the Company’s Decatur facility. Under the interim Consent Order, the Company’s principal obligations include commitments related to (i) future ongoing site operations such as (a) providing certain notices or reports and performing various analytical and characterization studies and (b) future capital improvements; and (ii) remediation activities, including certain on-site and off-site investigations and studies. Obligations related to ongoing future site operations under the Consent Order will involve additional operating costs and capital expenditures over multiple years. The Company does not expect them to have a material impact on its consolidated results of operations or financial position. With respect to remediation activities, financial obligations related to certain activities under the Consent Order are probable and estimable, and are included in the Company’s accruals for “other environmental liabilities” as described in the “Environmental Liabilities and Insurance Receivables” section below. As offsite investigation activities continue, additional remediation amounts may become probable and estimable in the future.
In December 2019, the Company received a grand jury subpoena from the U.S. Attorney’s Office for the Northern District of Alabama for documents related to, among other matters, the Company’s compliance with the 2009 TSCA consent order and unpermitted discharges to the Tennessee River. The Company is cooperating with this inquiry and is producing documents in response to the subpoena.
In addition, as part of its ongoing evaluation of regulatory compliance at its Cordova, Illinois facility, the Company discovered it had not fully characterized its PFAS discharge in its NPDES permit for the Cordova facility. In November 2019, the Company disclosed this matter to the EPA, and in January 2020 disclosed this matter to the Illinois Environmental Protection Agency (IEPA). The Company continues to work with the EPA and IEPA to address the discharge from the Cordova facility.
The Company is also reviewing operations at its other plants with similar manufacturing processes, such as the plant in Cottage Grove, Minnesota, to ensure those operations are in compliance with applicable environmental regulatory requirements and Company policies and procedures. As a result of these reviews, the Company discovered it had not fully characterized its PFAS discharge in its NPDES permit for the Cottage Grove facility. In March 2020, the Company disclosed this matter to the Minnesota Pollution Control Agency (MPCA) and the EPA. In July 2020, the Company received an information request from MPCA for documents and information related to, among other matters, the Company’s compliance with the Clean Water Act at its Cottage Grove facility. The Company is cooperating with this inquiry and will be producing documents and information in response to the request for information. The Company continues to work with the MPCA and EPA to address the discharges from the Cottage Grove facility.
Separately, in June 2020, the Company reported to EPA and MPCA that it had not fully complied with elements of the inspection, characterization and waste stream profile verification process of the Waste and Feedstream Analysis plan of its Resource Conservation and Recovery Act permit for its Cottage Grove incinerator.
In February 2020, the Company received an information request from EPA for documents and information related to, among other matters, the Company’s compliance with the Clean Water Act at its facilities that manufacture, process and use PFAS, including the Decatur, Cordova and Cottage Grove facilities. The Company is cooperating with this inquiry and is producing documents and information in response to the request for information.
The Company will continue to work with relevant state and federal agencies as it conducts these reviews.
The Company cannot predict at this time the outcomes of resolving these compliance matters or what potential actions may be taken by the regulatory agencies.
Other Environmental Litigation
In July 2018, the Company, along with more than
46
For environmental matters and litigation described above, unless otherwise stated,
Environmental Liabilities and Insurance Receivables
The Company periodically examines whether the contingent liabilities related to the environmental matters and litigation described above are probable and estimable based on experience and developments in those matters. During the six months ended June 30, 2020, the Company increased its accrual for PFAS-related other environmental liabilities by $
As of June 30, 2020, the Company had recorded liabilities of $
It is difficult to estimate the cost of environmental compliance and remediation given the uncertainties regarding the interpretation and enforcement of applicable environmental laws and regulations, the extent of environmental contamination and the existence of alternative cleanup methods. Developments may occur that could affect the Company’s current assessment, including, but not limited to: (i) changes in the information available regarding the environmental impact of the Company’s operations and products; (ii) changes in environmental regulations, changes in permissible levels of specific compounds in drinking water sources, or changes in enforcement theories and policies, including efforts to recover natural resource damages; (iii) new and evolving analytical and remediation techniques; (iv) success in allocating liability to other potentially responsible parties; and (v) the financial viability of other potentially responsible parties and third-party indemnitors. For sites included in both “environmental remediation liabilities” and “other environmental liabilities,” at which remediation activity is largely complete and remaining activity relates primarily to operation and maintenance of the remedy, including required post-remediation monitoring, the Company believes the exposure to loss in excess of the amount accrued would not be material to the Company’s consolidated results of operations or financial condition. However, for locations at which remediation activity is largely ongoing, the Company cannot estimate a possible loss or range of loss in excess of the associated established accruals for the reasons described above.
The Company has both pre-1986 general and product liability occurrence coverage and post-1985 occurrence reported product liability and other environmental coverage for environmental matters and litigation. As of June 30, 2020, the Company’s receivable for insurance recoveries related to the environmental matters and litigation was $
47
(ii) the extent to which insurers may become insolvent in the future, (iii) the outcome of negotiations with insurers, and (iv) the scope of the insurers’ purported defenses and exclusions to avoid coverage.
Product Liability Litigation
As of June 30, 2020, the Company was a named defendant in
As previously disclosed, 3M had been a named defendant in lawsuits in federal courts involving over
The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all cases pending in federal courts to the U.S. District Court for the District of Minnesota to be managed in a multi-district litigation (MDL) proceeding. In July 2019, the court excluded several of the plaintiffs’ causation experts, and granted summary judgment for 3M in all cases pending at that time in the MDL. Plaintiffs have appealed that decision to the U.S. Court of Appeals for the Eighth Circuit. Plaintiffs have also appealed a 2018 jury verdict in favor of 3M in the first bellwether trial in the MDL and appealed the dismissal of another bellwether case.
Among the
As previously disclosed, 3M had been named a defendant in
In June 2016, the Company was served with a putative class action filed in the Ontario Superior Court of Justice for all Canadian residents who underwent various joint arthroplasty, cardiovascular, and other surgeries and later developed surgical site infections due to the use of the Bair Hugger™ patient warming system. The representative plaintiff seeks relief (including punitive damages) under Canadian law based on theories similar to those asserted in the MDL.
Aearo Technologies sold Dual-Ended Combat Arms – Version 2 earplugs starting in about 2003. 3M acquired Aearo Technologies in 2008 and sold these earplugs from 2008 through 2015, when the product was discontinued. In December 2018, a military veteran filed an individual lawsuit against 3M in the San Bernardino Superior Court in California alleging that he sustained personal injuries while serving in the military caused by 3M’s Dual-Ended Combat Arms earplugs – Version 2. The plaintiff asserts claims of product liability and fraudulent misrepresentation and concealment. The plaintiff seeks various damages, including medical and related expenses, loss of income, and punitive damages. As of June 30, 2020, the Company is a named defendant in approximately
48
in a multi-district litigation (MDL) proceeding to centralize pre-trial proceedings. Discovery is underway. The plaintiffs and 3M filed preliminary summary judgment motions on the government contractor defense. In July 2020, based on the current record, the court granted the plaintiffs’ summary judgment motion and denied the defendants’ summary judgment motion, ruling that plaintiffs’ claims are not barred by the government contractor defense. The first bellwether case is scheduled for April 2021.
For product liability litigation matters described in this section for which a liability has been recorded, the amount recorded is not material to the Company’s consolidated results of operations or financial condition. In addition, the Company is not able to estimate a possible loss or range of loss in excess of the established accruals at this time.
Securities Litigation
In July 2019, Heavy & General Laborers’ Locals 472 & 172 Welfare Fund filed a putative securities class action against 3M Company, its former Chairman and CEO, current Chairman and CEO, and current CFO in the U.S. District Court for the District of New Jersey. In August 2019, an individual plaintiff filed a similar putative securities class action in the same district. Plaintiffs allege that defendants made false and misleading statements regarding 3M's exposure to liability associated with PFAS, and bring claims for damages under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against all defendants, and under Section 20(a) of the Securities and Exchange Act of 1934 against the individual defendants. In October 2019, the court consolidated the securities class actions and appointed a group of lead plaintiffs. In January 2020, defendants filed a motion to transfer venue to the U.S. District Court for the District of Minnesota. The suit is in the early stages of litigation.
In October 2019, a follow-on derivative lawsuit was filed in the U.S. District Court for the District of New Jersey against 3M and several of its current and former executives and directors. In November and December 2019,
Federal False Claims Act / Qui Tam Litigation
In October 2019, 3M acquired Acelity, Inc. and its KCI subsidiaries, including Kinetic Concepts, Inc. and KCI USA, Inc. As previously disclosed in the SEC filings by the KCI entities, in 2009, Kinetic Concepts, Inc. received a subpoena from the U.S. Department of Health and Human Services Office of Inspector General. In 2011, following the completion of the government’s review and its decision declining to intervene in
The government inquiry followed
In October 2016, the KCI Defendants filed counterclaims in the Godecke case, asserting breach of contract and conversion. In August 2017, the relator-plaintiff’s fraud claim in the Godecke case was dismissed in favor of the KCI defendants. In January 2018, the district court stayed the retaliation claim and the KCI Defendants' counterclaims pending the relator-plaintiff’s appeal. In September 2019, the U.S. Court of Appeals for the Ninth Circuit reversed and remanded the case to the district court for further proceedings. The district court has ordered a stay of the proceedings pending a status conference in August 2020. Separately, in June 2019, following discovery, the district court in the second case (the “Hartpence case”) entered summary judgment in the KCI Defendants’ favor on all of the relator-plaintiff’s claims. The plaintiff then filed an appeal in the U.S. Court of Appeals for the Ninth Circuit. Oral argument in the Hartpence case was held in July 2020. The appellate court’s opinion remains pending.
49
Compliance Matter
The Company, through its internal processes, discovered certain travel activities and related funding and record keeping issues raising concerns, arising from marketing efforts by certain business groups based in China. The Company initiated an internal investigation to determine whether the expenditures may have violated the U.S. Foreign Corrupt Practices Act (FCPA) or other potentially applicable anti-corruption laws. The Company has retained outside counsel and a forensic accounting firm to assist with the investigation. In July 2019, the Company voluntarily disclosed this investigation to both the Department of Justice and Securities and Exchange Commission and is cooperating with both agencies. The Company cannot predict at this time the outcome of its investigation or what potential actions may be taken by the Department of Justice or Securities and Exchange Commission.
NOTE 15. Stock-Based Compensation
The 3M 2016 Long-Term Incentive Plan provides for the issuance or delivery of up to
The Company’s annual stock option and restricted stock unit grant is made in February to provide a strong and immediate link between the performance of individuals during the preceding year and the size of their annual stock compensation grants. The grant to eligible employees uses the closing stock price on the grant date. Accounting rules require recognition of expense under a non-substantive vesting period approach, requiring compensation expense recognition when an employee is eligible to retire. Employees are considered eligible to retire at age
In addition to the annual grants, the Company makes other minor grants of stock options, restricted stock units and other stock-based grants. The Company issues cash settled restricted stock units and stock appreciation rights in certain countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company.
Amounts recognized in the financial statements with respect to stock-based compensation programs, which include stock options, restricted stock, restricted stock units, performance shares and the General Employees’ Stock Purchase Plan (GESPP), are provided in the following table. Capitalized stock-based compensation amounts were not material for the three and six months ended June 30, 2020 and 2019.
Stock-Based Compensation Expense
Three months ended | Six months ended |
| |||||||||||
June 30, | June 30, | ||||||||||||
(Millions) |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| ||||
Cost of sales | $ | | $ | | $ | | $ | | |||||
Selling, general and administrative expenses |
| |
| |
| |
| | |||||
Research, development and related expenses |
| |
| |
| |
| | |||||
Stock-based compensation expenses | $ | | $ | | $ | | $ | | |||||
Income tax benefits | ( | ( | ( | ( | |||||||||
Stock-based compensation expenses (benefits), net of tax | $ | | $ | | $ | | $ | | |||||
50
Stock Option Program
The following table summarizes stock option activity during the six months ended June 30, 2020:
Weighted | |||||||||||
Average | |||||||||||
|
| Weighted |
| Remaining |
| Aggregate | |||||
Number of | Average | Contractual | Intrinsic Value | ||||||||
(Options in thousands) | Options | Exercise Price | Life (months) | (millions) | |||||||
Under option — | |||||||||||
January 1 |
| | $ | |
|
| |||||
Granted: | |||||||||||
Annual |
| |
| |
|
|
| ||||
Exercised |
| ( |
| |
|
|
| ||||
Forfeited |
| ( |
| |
|
|
| ||||
June 30 |
| | $ | |
| $ | |
| |||
Options exercisable | |||||||||||
June 30 |
| | $ | |
| $ | |
| |||
Stock options vest over a period from
For the primary 2020 annual stock option grant, the weighted average fair value at the date of grant was calculated using the Black-Scholes option-pricing model and the assumptions that follow.
Stock Option Assumptions
Annual | ||||
| 2020 | |||
Exercise price | $ | | ||
Risk-free interest rate |
| | % | |
Dividend yield |
| | % | |
Expected volatility |
| | % | |
Expected life (months) |
| |||
Black-Scholes fair value | $ | | ||
Expected volatility is a statistical measure of the amount by which a stock price is expected to fluctuate during a period. For the 2020 annual grant date, the Company estimated the expected volatility based upon the following three volatilities of 3M stock: the median of the term of the expected life rolling volatility; the median of the most recent term of the expected life volatility; and the implied volatility on the grant date. The expected term assumption is based on the weighted average of historical grants.
Restricted Stock and Restricted Stock Units
The following table summarizes restricted stock and restricted stock unit activity during the six months ended June 30, 2020:
51
| ||||||
|
|
| Weighted |
| ||
Average |
| |||||
Number of | Grant Date |
| ||||
(Shares in thousands) | Shares | Fair Value |
| |||
Nonvested balance — | ||||||
As of January 1 |
| | $ | | ||
Granted | ||||||
Annual |
| |
| | ||
Other |
| |
| | ||
Vested |
| ( |
| | ||
Forfeited |
| ( |
| | ||
As of June 30 |
| | $ | | ||
As of June 30, 2020, there was $
Restricted stock units granted generally vest
Performance Shares
Instead of restricted stock units, the Company makes annual grants of performance shares to members of its executive management. The 2020 performance criteria for these performance shares (organic volume growth, return on invested capital, free cash flow conversion, and earnings per share growth) were selected because the Company believes that they are important drivers of long-term stockholder value. The number of shares of 3M common stock that could actually be delivered at the end of the performance period may be anywhere from
52
The following table summarizes performance share activity during the six months ended June 30, 2020:
| ||||||
|
|
| Weighted |
| ||
Average |
| |||||
Number of | Grant Date |
| ||||
(Shares in thousands) | Shares | Fair Value |
| |||
Undistributed balance — | ||||||
As of January 1 |
| | $ | | ||
Granted |
| |
| | ||
Distributed |
| ( |
| | ||
Performance change |
| |
| | ||
Forfeited |
| ( |
| | ||
As of June 30 |
| | $ | | ||
As of June 30, 2020, there was $
NOTE 16. Business Segments
3M’s businesses are organized, managed and internally grouped into segments based on differences in markets, products, technologies and services. 3M manages its operations in
Effective in the second quarter of 2020, the measure of segment operating performance used by 3M’s chief operating decision maker (CODM) changed and, as a result, 3M’s disclosed measure of segment profit/loss (business segment operating income) has been updated for all periods presented. The change to business segment operating income aligns with the update to how the CODM assesses performance and allocates resources for the Company’s business segments.
3M discloses business segment operating income as its measure of segment profit/loss, reconciled to both total 3M operating income and income before taxes. Business segment operating income includes dual credit for certain related operating income (as described below in “Elimination of Dual Credit”). Business segment operating income excludes certain expenses and income that are not allocated to business segments (as described below in “Corporate and Unallocated”). Additionally, the following special items are excluded from business segment operating income and, instead, are included within Corporate and Unallocated: significant litigation-related charges/benefits, gain/loss on sale of businesses (see Note 3), and divestiture-related restructuring actions (see Note 5).
In addition, effective in the first quarter of 2020, in a continuing effort to improve the alignment of its businesses around customers and markets, the Company made the following changes:
Continued alignment of customer account activity
| ● | As part of 3M’s regular customer-focus initiatives, the Company realigned certain customer account activity (“sales district”) to correlate with the primary divisional product offerings in various countries and reduce complexity for customers when interacting with multiple 3M businesses. This largely impacted the amount of dual credit certain business segments receive as a result of sales district attribution. 3M business segment reporting measures include dual credit to business segments for certain sales and operating income. This dual credit is based on which business segment provides customer account activity with respect to a particular product sold in a specific country. As a result of this change, previously reported aggregate |
53
| business segment net sales and operating income for the total year 2019 decreased $ |
Additional actions impacting product line alignments
| ● | The remaining retail auto care product lines formerly in the Automotive Aftermarket Division (within the Safety and Industrial business segment), were realigned to the Construction and Home Improvement Division (within the Consumer business segment). This change resulted in a decrease of previously reported net sales and operating income for total year 2019 of $ |
| ● | In addition, certain product lines were realigned within business segments. The transdermal drug delivery components business, formerly included in the Drug Delivery Systems Division, was realigned to the Medical Solutions Division (both of which are within the Health Care business segment) and the paint protection film business, formerly included in the Automotive and Aerospace Division, was realigned to the Commercial Solutions Division (both of which are within the Transportation and Electronics business segment). |
The financial information presented herein reflects the impact of the preceding changes for all periods presented.
Business Segment Information
Three months ended | Six months ended |
| |||||||||||
June 30, | June 30, |
| |||||||||||
Net Sales (Millions) |
| 2020 |
| 2019 |
| 2020 |
| 2019 |
| ||||
Safety and Industrial |
| $ | |
| $ | |
| $ | |
| $ | | |
Transportation and Electronics |
| |
| |
| |
| | |||||
Health Care |
| |
| |
| |
| | |||||
Consumer |
| |
| |
| |
| | |||||
Corporate and Unallocated |
| ( |
| |
| ( |
| | |||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| ( | |||||
Total Company |
| $ | |
| $ | |
| $ | |
| $ | | |
Operating Performance (Millions) | |||||||||||||
Safety and Industrial |
| $ | |
| $ | |
| $ | |
| $ | | |
Transportation and Electronics |
| |
| |
| |
| | |||||
Health Care |
| |
| |
| |
| | |||||
Consumer |
| |
| |
| |
| | |||||
Elimination of Dual Credit |
| ( |
| ( |
| ( |
| ( | |||||
Total business segment operating income |
| $ | |
| $ | |
| $ | |
| $ | | |
Corporate and Unallocated | |||||||||||||
Special items: | |||||||||||||
Significant litigation-related (charges)/benefits | $ | — | $ | — | $ | ( | $ | ( | |||||
Gain/(loss) on sale of businesses | | — | | | |||||||||
Divestiture-related restructuring actions | ( | — | ( | — | |||||||||
Other corporate expense - net |
| ( |
| ( |
| ( |
| ( | |||||
Total Corporate and Unallocated | | ( | | ( | |||||||||
Total Company operating income | $ | | $ | | $ | | $ | | |||||
Other expense/(income), net | $ | | $ | | $ | | $ | | |||||
Income before income taxes | $ | | $ | | $ | | $ | | |||||
Corporate and Unallocated
Corporate and unallocated operating income includes a variety of miscellaneous items, such as corporate investment gains and losses, certain derivative gains and losses, certain insurance-related gains and losses, certain litigation and environmental expenses, corporate restructuring charges and certain under- or over-absorbed costs (e.g. pension, stock-based compensation) that the Company may choose not to allocate directly to its business segments and is disclosed as “other corporate expense-net”. Additionally, Corporate and
54
Unallocated includes special items such as significant litigation-related charges/benefits, gain/loss on sale of businesses (see Note 3), and divestiture-related restructuring costs (see Note 5). Corporate and Unallocated also includes sales, costs, and income from contract manufacturing, transition services and other arrangements with the acquirer of the Communication Markets Division following its 2018 divestiture through 2019. Because this category includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis.
Elimination of Dual Credit
3M business segment reporting measures include dual credit to business segments for certain sales and related operating income. Management evaluates each of its
55
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of 3M’s financial statements with a narrative from the perspective of management. 3M’s MD&A is presented in the following sections:
| ● | Overview |
| ● | Results of Operations |
| ● | Performance by Business Segment |
| ● | Financial Condition and Liquidity |
| ● | Cautionary Note Concerning Factors That May Affect Future Results |
Forward-looking statements in Part I, Item 2 may involve risks and uncertainties that could cause results to differ materially from those projected (refer to the section entitled “Cautionary Note Concerning Factors That May Affect Future Results” in Part I, Item 2 and the risk factors provided in Part II, Item 1A for discussion of these risks and uncertainties).
OVERVIEW
3M is a diversified global manufacturer, technology innovator and marketer of a wide variety of products and services. As described in Note 16, effective in the second quarter of 2020, the measure of segment operating performance used by 3M’s chief operating decision maker changed and, as a result, the Company’s disclosed measure of segment profit/loss has been updated. Also, effective in the first quarter of 2020, the Company changed its business segment reporting in its continuing effort to improve the alignment of businesses around markets and customers. Additionally, the Company consolidated the way it presents geographic area net sales by providing an aggregate Americas geographic region (combining former United States and Latin America and Canada areas). Information provided herein reflects the impact of these changes for all periods presented.
3M manages its operations in four operating business segments: Safety and Industrial; Transportation and Electronics; Health Care; and Consumer. From a geographic perspective, any references to EMEA refer to Europe, Middle East and Africa on a combined basis.
Consideration of COVID-19:
3M is impacted by the global pandemic and related effects associated with the coronavirus (COVID-19). The Company updated its risk factors with respect to COVID-19, which can be found in Item 1A “Risk Factors” in this document.
Public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted 3M’s operations. 3M is working to protect its employees and the public, maintain business continuity and sustain its operations, including ensuring the safety and protection of people who work in its plants and distribution centers across the world, many of whom support the manufacturing and delivery of products that are critical in response to the global pandemic. COVID-19 has impacted 3M’s supply chains relative to global demand for products like respirators, surgical masks and commercial cleaning solutions. As this situation continues, 3M is also closely monitoring and responding to potential impacts to the Company’s broader supply chain associated with other products. COVID-19 has also affected the ability of suppliers and vendors to provide products and services to 3M. Furthermore, COVID-19 has impacted the broader economies of affected countries, including negatively impacting economic growth.The Company has taken steps to help employees lead safe and productive lives during the outbreak including remote working; escalated procedures in factories related to personal safety, cleaning and medical screening measures; and pandemic leave policies. 3M is closely monitoring how the spread of COVID-19 is affecting employees and business operations and has developed preparedness plans to help protect the safety of employees around the world while safely continuing business. While nearly all of our manufacturing locations and distribution centers are fully or partially operational, the Company implemented plant and/or line shutdowns related to certain markets due to weaker customer demand or government mandates. Some of the above factors have increased the demand for 3M products, while others have decreased demand or made it more difficult for 3M to serve customers. Serving 3M customers is a priority and teams continue to communicate with individual customers about potential disruptions.
3M’s total sales decreased 12.2% and 4.9% year-on-year in the second quarter and first six months of 2020, respectively. Organic local-currency sales decreased 13.1% and 6.5% year-on-year in the second quarter and first six months of 2020, respectively. Given the diversity of 3M’s businesses, the impact of COVID-19 varied across the Company in the second quarter and first six months of
56
2020. 3M experienced strong sales growth in personal safety, as well as in other areas such as home improvement, general cleaning, semiconductor, data center, and biopharma filtration. COVID-related respirator sales are estimated to have impacted year-over-year organic local-currency sales growth by just under 3 percent and just over 2 percent for the second quarter and first six months of 2020, respectively. At the same time, 3M saw weak demand in several end markets, contributing in part to sales declines in a number of 3M’s businesses with the biggest year over year second quarter total sales decreases in oral care (down 58 percent), automotive and aerospace (down 44 percent), automotive aftermarket (down 33 percent), commercial solutions (down 31 percent), stationery and office (down 25 percent), and businesses aligned to general industrial applications such as industrial adhesives and tapes (down 18 percent) and abrasives (down 32 percent).
3M’s operating income margins increased 3.5 and 4.6 percentage points year-on-year in the second quarter and first six months of 2020, respectively. Factoring out the impact on operating income of special items as described in the Certain amounts adjusted for special items - (non-GAAP measures) section below, operating income margins decreased 1.2 and 0.9 percentage points to 19.6 percent and 20.2 percent, respectively, for the second quarter and first six months of 2020 when compared the same periods in 2019. Various COVID-19 implications contributed in part to these decreases.
Overall, the impact of the COVID-19 pandemic on 3M’s consolidated results of operations was primarily driven by factors related to changes in demand for products and disruption in global supply chains as described above. While it is not feasible to identify or quantify all the other direct and indirect implications on 3M’s results of operations, below are factors that 3M believes have also impacted its operating income for the second quarter and first six months of 2020:
Factors contributing to charges:
| ● | Period expenses of unabsorbed manufacturing costs and increased expected credit losses on customer receivables. |
| ● | Restructuring actions addressing structural enterprise costs and operations in certain end markets as a result of the COVID-19 pandemic and related economic impact resulting in a second quarter 2020 charge of $58 million (as further discussed in Note 5). |
| ● | Committed financial support to various COVID-relief and medical research initiatives. |
| ● | Charge of $22 million related to equity securities as discussed in the “Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis” section of Note 13 that use the measurement alternative described therein in addition to an immaterial pre-tax charge related to impairment of certain indefinite lived tradenames in the first quarter of 2020. |
Factors providing benefits:
| ● | Decreased discretionary spending in areas such as travel, professional services, and advertising/merchandising as well as cost reduction efforts, hiring freezes, and maintaining only essential contract workers. |
| ● | Government-sponsored COVID-response stimulus and relief initiatives, including certain employment retention benefits under the Coronavirus Aid, Relief and Economic Security (CARES) Act in the United States. |
| ● | Lower incentive compensation and self-insured medical visit/instance expense. |
| ● | Instituted accelerated vacation usage policies which benefit the second quarter of 2020 year-over-year. |
3M plans to monitor discretionary spending and cost control efforts as the situation continues.
3M continues to consider if COVID-19 and other related market implications could indicate it is more likely than not the carrying amount of various applicable assets may be impaired and assess whether certain investments without readily determinable fair values may have been impacted.
As previously disclosed, in light of circumstances, 3M took actions to ensure sources of cash may remain strong, including the March 2020 issuance of $1.75 billion of registered notes, suspension of share repurchases, and lowering its original $1.6 billion to $1.8 billion range of full year 2020 estimated capital spending which was further updated during the second quarter of 2020 to approximately $1.4 billion. While estimated capital spending decreased, it includes additional expansion of respirator production capacity. 3M continues to have access to its commercial paper program and undrawn committed credit facility. Refer to the Financial Condition and Liquidity section below for more information on the Company’s liquidity position.
The Company also continues to evaluate the extent to which it may avail itself of various government-sponsored COVID-response stimulus, relief, and production initiatives around the world, such as under the Defense Production Act (DPA) and CARES Act in the United States. In the second quarter of 2020, under the DPA, the U.S. government initiated certain agreements with 3M involving just
57
over $200 million of anticipated funding of assets to expand capacity to supply N-95 respirators to the U.S. government. The nature of the agreement provides a program of expedited partial funding to begin expansion while final terms are completed.
Due to the speed with which the COVID-19 situation is developing and evolving and the uncertainty of its duration and the timing of recovery, 3M is not able at this time to predict the extent to which the COVID-19 pandemic may have a material effect on its consolidated results of operations or financial condition.
Earnings per share attributable to 3M common shareholders – diluted:
The following table provides the increase (decrease) in diluted earnings per share for the three and six months ended June 30, 2020 and 2019.
Three months ended | Six months ended | ||||||
(Earnings per diluted share) |
| June 30, 2020 |
| June 30, 2020 |
| ||
Same period last year | $ | 1.92 | $ | 3.44 | |||
Significant litigation-related charges/benefits | — | 0.72 | |||||
Loss on deconsolidation of Venezuelan subsidiary | 0.28 | 0.28 | |||||
Gain/loss on sale of businesses | (0.07) | (0.09) | |||||
Same period last year, excluding special items | $ | 2.13 | $ | 4.35 | |||
Increase/(decrease) in earnings per share - diluted, due to: | |||||||
Organic growth/productivity and other | (0.28) | (0.22) | |||||
Acquisitions/divestitures | (0.07) | (0.12) | |||||
Foreign exchange impacts | (0.05) | (0.13) | |||||
Income tax rate | 0.03 | 0.01 | |||||
Shares of common stock outstanding | 0.02 | 0.04 | |||||
Current period, excluding special items | $ | 1.78 | $ | 3.93 | |||
Significant litigation-related charges/benefits | — | 0.07 | |||||
Gain/loss on sale of businesses | 0.52 | 0.52 | |||||
Divestiture-related restructuring actions | (0.08) | (0.08) | |||||
Current period | $ | 2.22 | $ | 4.44 | |||
For the second quarter of 2020, net income attributable to 3M was $1.3 billion, or $2.22 per diluted share compared to $1.1 billion or $1.92 per diluted share in the same period last year, an increase of 15.6 percent on a per diluted share basis. For the first six months of 2020 net income attributable to 3M was $2.6 billion, or $4.44 per diluted share compared to $2.0 billion or $3.44 per diluted share in the same period last year, an increase of 29.1 percent on a per diluted share basis.
The Company refers to various amounts or measures on an “adjusted basis”. These exclude special items. These non-GAAP measures are further described and reconciled to the most directly comparable GAAP financial measures in the Certain amounts adjusted for special items - (non-GAAP measures) section below.
On an adjusted basis for the second quarter 2020, net income attributable to 3M was $1.0 billion, or $1.78 per diluted share versus $1.2 billion, or $2.13 per diluted share in the same period last year, which was a decrease of 16.4 percent on a per diluted share basis. On an adjusted basis for the first six months of 2020, net income attributable to 3M was $2.3 billion, or $3.93 per diluted share versus $2.6 billion, or $4.35 per diluted share for the same period last year, which was a decrease of 9.7 percent on a per diluted share basis.
Additional discussion related to the components of the year-on-year change in earnings per diluted share follows:
58
Organic growth/productivity and other:
| ● | Lower organic local-currency sales growth as a result of significant COVID-19 related impacts, in addition to COVID-related net factors described in the preceding Overview—Consideration of COVID-19 section decreased earnings per diluted share year-on-year. These net factors included cost saving actions taken in response to COVID-19 but also reflected 2020 charges for items such as restructuring actions addressing structural enterprise costs and operations in certain end markets as a result of the COVID-19 pandemic and related economic impact (further described in Note 5). Partially offsetting this net decrease were benefits recognized in the first six months of 2020 related to the restructuring and other actions taken in 2019. |
| ● | On a combined basis, higher defined benefit pension and postretirement service cost increased expense year-on-year. |
| ● | Interest expense (net of interest income) increased year-on-year for both the second quarter and first six months of 2020, as a result of higher U.S. average debt balances and lower year-on-year interest income driven by lower average interest rates on cash balances. |
Acquisitions/divestitures:
| ● | Acquisition impacts, which are measured for the first twelve months post-transaction, relate to the acquisitions of M*Modal (first quarter 2019), and Acelity (fourth quarter 2019). These items collectively decreased earnings per diluted share by 4 cents and 9 cents year-on-year for the second quarter and first six months of 2020, respectively. The net impacts related to these acquisitions included income from operations, more than offset by transaction and integration costs. Financing costs related to these acquisitions is also included. |
| ● | Divestiture impacts include the lost operating income from divested businesses, which decreased earnings per diluted share by 3 cents for both the second quarter and first six months of 2020. This was primarily related to the divestiture of the Company’s drug delivery business. |
Foreign exchange impacts:
| ● | Foreign currency impacts (net of hedging) decreased pre-tax earnings year-on-year by approximately $37 million and $95 million, or the equivalent of 5 cents and 13 cents per diluted share the second quarter and first six months of 2020, respectively, excluding the impact of foreign currency changes on tax rates. |
Income tax rate:
| ● | Certain items above reflect specific income tax rates associated with those items. Overall, the effective tax rate for the second quarter of 2020 was 21.0 percent, a decrease of 0.8 percentage points versus 2019. The effective tax rate for the first six months of 2020 was 19.2 percent, a decrease of 0.9 percentage points versus 2019. Excluding the special items (as discussed below), the effective tax rate decreased 1.6 percentage points and 0.2 percentage points year-on-year for the second quarter and first six months of 2020, respectively. |
| ● | Factors that decreased the effective tax rate for the second quarter year-over-year were the 2019 non-deductible charge related to the deconsolidation of the Venezuelan subsidiary, adjustments to uncertain tax positions not repeating in 2020 and increased year-over-year benefit from US international tax provisions. These decreases were partially offset by the 2019 tax benefit that did not repeat related to the “held for sale” status of legal entities associated with the then pending divestiture of the gas and flame detection business and decreased year-over-year benefit from stock options. |
| ● | Factors that decreased the effective rate for the first six months of 2020 year-over-year include the 2019 non-deductible charge related to the deconsolidation of the Venezuelan subsidiary, adjustments to uncertain tax positions not repeating in 2020, 2020 resolution of the tax treatment of the 2018 NRD lawsuit, and increased year-over-year benefit from US international tax provisions. These decreases were partially offset by the 2019 tax benefit that did not repeat related to the “held for sale” status of legal entities associated with the then-pending divestiture of the gas and flame detection business and decreased year-over-year benefit from stock options. |
Shares of common stock outstanding:
| ● | Lower shares outstanding increased earnings per share year-on-year by 2 cents and 4 cents per diluted share for the second quarter and first six months of 2020. Weighted-average diluted shares outstanding in the second quarter and first six months of 2020 declined 0.9 percent and 1.0 percent year-on-year, respectively, which benefited earnings per share. The decrease in the outstanding weighted-average diluted shares relates to the Company’s purchase $366 million of its own stock in the first six months of 2020, prior to 3M’s suspension of its stock repurchase program in late March 2020. |
59
Certain amounts adjusted for special items - (non-GAAP measures):
In addition to reporting financial results in accordance with U.S. GAAP, the Company also provides non-GAAP measures that adjust for the impacts of special items. For the periods presented, special items include the items described below. Beginning in 2020, the Company includes gain/loss on sale of businesses and divestiture-related restructuring actions as special items due to their potential distortion of underlying operating results. Information provided herein reflects the impact of this change for all periods presented. Operating income (measure of segment operating performance), income before taxes, net income, earnings per share, and the effective tax rate are all measures for which 3M provides the reported GAAP measure and a measure adjusted for special items. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. The Company considers these non-GAAP measures in evaluating and managing the Company’s operations. The Company believes that discussion of results adjusted for these items is meaningful to investors as it provides a useful analysis of ongoing underlying operating trends. The determination of these items may not be comparable to similarly titled measures used by other companies. Special items include:
Significant litigation-related charges/benefits:
| ● | In the first quarter of 2020, 3M recorded a net pre-tax charge of $17 million ($13 million after tax) related to PFAS (certain perfluorinated compounds) matters. The charge was more than offset by a reduction in tax expense of $52 million related to resolution of tax treatment with authorities regarding the previously disclosed 2018 agreement reached with the State of Minnesota that resolved the Natural Resources Damages (NRD) lawsuit. These items, in aggregate, resulted in a $39 million after tax benefit. |
| ● | In the first quarter of 2019, 3M recorded significant litigation-related charges of $548 million ($424 million after tax) related to historical PFAS manufacturing operations and coal mine dust respirator mask lawsuits as further discussed in Note 14. These were reflected in cost of sales ($223 million) and selling, general and administrative expense ($325 million). |
Loss on deconsolidation of Venezuelan subsidiary:
| ● | In the second quarter of 2019, 3M recorded a pre-tax charge of $162 million related to the deconsolidation of the Company’s Venezuelan subsidiary as further discussed in Note 1. |
Gain/loss on sale of businesses:
| ● | In the first quarter of 2020, 3M recorded a pre-tax gain of $2 million ($1 million loss after tax) related to the sale of its advanced ballistic-protection business and recognition of certain contingent consideration. In the second quarter of 2020, 3M recorded a pre-tax gain of $387 million ($304 million after tax) related to the sale of its drug delivery business. Refer to Note 3 for further details. |
| ● | In the first quarter of 2019, 3M recorded a gain related to the sale of certain oral care technology comprising a business in addition to reflecting an earnout on a previous divestiture, which together resulted in a net gain of $8 million ($7 million after tax). In the second quarter of 2019, as a result of a “held for sale” tax benefit related to the legal entities associated with the pending divestiture of the Company’s gas and flame detection business, 3M recorded an after tax gain of $43 million. |
Divestiture-related restructuring actions:
| ● | In the second quarter 2020, following the divestiture of substantially all of the drug delivery business (see Note 3) management approved and committed to undertake certain restructuring actions addressing corporate functional costs and manufacturing footprint across 3M in relation to the magnitude of amounts previously allocated/burdened to the divested business. As a result, 3M recorded a pre-tax charge of $55 million ($46 million after tax). Refer to Note 5 for further details. |
60
(Dollars in millions, except per share amounts) | Operating Income | Operating Income Margin | Income Before Taxes | Provision for Income Taxes | Effective Tax Rate | Net Income Attributable to 3M | Earnings Per Diluted Share | Earnings per diluted share percent change | ||||||||||||||
Three months ended June 30, 2019 GAAP | $ | 1,702 | 20.8 | % | $ | 1,446 | $ | 315 | 21.8 | % | $ | 1,127 | $ | 1.92 | ||||||||
Adjustments for special items: | ||||||||||||||||||||||
Gain/loss on sale of businesses | — | 43 | (43) | (0.07) | ||||||||||||||||||
Loss on deconsolidation of Venezuelan subsidiary |
| — | 162 | — | 162 | 0.28 | ||||||||||||||||
Three months ended June 30, 2019 adjusted amounts (non-GAAP measures) | $ | 1,702 | 20.8 | % | $ | 1,608 | $ | 358 | 22.3 | % | $ | 1,246 | $ | 2.13 | ||||||||
| ||||||||||||||||||||||
Three months ended June 30, 2020 GAAP |
| $ | 1,740 | 24.3 | % | $ | 1,629 | $ | 342 | 21.0 | % | $ | 1,290 | $ | 2.22 | 15.6 | % | |||||
Adjustments for special items: | ||||||||||||||||||||||
Gain/loss on sale of businesses | (387) | (387) | (83) | (304) | (0.52) | |||||||||||||||||
Divestiture-related restructuring actions | 55 | 55 | 9 | 46 | 0.08 | |||||||||||||||||
Three months ended June 30, 2020 adjusted amounts (non-GAAP measures) |
| $ | 1,408 | 19.6 | % | $ | 1,297 | $ | 268 | 20.7 | % | $ | 1,032 | $ | 1.78 | (16.4) | % |
(Dollars in millions, except per share amounts) | Operating Income | Operating Income Margin | Income Before Taxes | Provision for Income Taxes | Effective Tax Rate | Net Income Attributable to 3M | Earnings Per Diluted Share | Earnings per diluted share percent change | ||||||||||||||
Six months ended June 30, 2019 GAAP | $ | 2,838 | 17.7 | % | $ | 2,534 | $ | 510 | 20.1 | % | $ | 2,018 | $ | 3.44 | ||||||||
Adjustments for special items: | ||||||||||||||||||||||
Significant litigation-related charges/benefits | 548 | 548 | 124 | 424 | 0.72 | |||||||||||||||||
Gain/loss on sale of businesses | (8) | (8) | 42 | (50) | (0.09) | |||||||||||||||||
Loss on deconsolidation of Venezuelan subsidiary |
| — | 162 | — | 162 | 0.28 | ||||||||||||||||
Six months ended June 30, 2019 adjusted amounts (non-GAAP measures) | $ | 3,378 | 21.1 | % | $ | 3,236 | $ | 676 | 20.9 | % | $ | 2,554 | $ | 4.35 | ||||||||
| ||||||||||||||||||||||
Six months ended June 30, 2020 GAAP |
| $ | 3,403 | 22.3 | % | $ | 3,196 | $ | 615 | 19.2 | % | $ | 2,582 | $ | 4.44 | 29.1 | % | |||||
Adjustments for special items: | ||||||||||||||||||||||
Significant litigation-related charges/benefits | 17 | 17 | 56 | (39) | (0.07) | |||||||||||||||||
Gain/loss on sale of businesses | (389) | (389) | (86) | (303) | (0.52) | |||||||||||||||||
Divestiture-related restructuring actions | 55 | 55 | 9 | 46 | 0.08 | |||||||||||||||||
Six months ended June 30, 2020 adjusted amounts (non-GAAP measures) |
| $ | 3,086 | 20.2 | % | $ | 2,879 | $ | 594 | 20.7 | % | $ | 2,286 | $ | 3.93 | (9.7) | % |
61
Sales and operating income by business segment:
The following tables contain sales and operating income results by business segment for the three and six months ended June 30, 2020 and 2019. Refer to the section entitled “Performance by Business Segment” later in MD&A for additional discussion concerning 2020 versus 2019 results, including Corporate and Unallocated. Refer to Note 16 for additional information on business segments, including Elimination of Dual Credit.
Three months ended June 30, |
| ||||||||||||||||||
2020 | 2019 | % change | |||||||||||||||||
| Net |
| Oper. |
| Net | Oper. | Net | Oper. | |||||||||||
(Dollars in millions) | Sales | Income | Sales | Income | Sales | Income | |||||||||||||
Business Segments | |||||||||||||||||||
Safety and Industrial | $ | 2,668 |
| $ | 636 | $ | 2,937 |
| $ | 647 |
| (9.2) | % | (1.6) | % | ||||
Transportation and Electronics |
| 1,937 |
|
| 382 |
| 2,450 |
|
| 591 |
| (20.9) | (35.4) | ||||||
Health Care |
| 1,825 |
|
| 306 |
| 1,831 |
|
| 483 |
| (0.4) | (36.7) | ||||||
Consumer |
| 1,238 |
|
| 287 |
| 1,320 |
|
| 273 |
| (6.2) | 4.8 | ||||||
Corporate and Unallocated |
| (2) |
|
| 252 |
| 48 |
|
| (192) |
| — | — | ||||||
Elimination of Dual Credit |
| (490) |
|
| (123) |
| (415) |
|
| (100) |
| — | — | ||||||
Total Company | $ | 7,176 |
| $ | 1,740 | $ | 8,171 |
| $ | 1,702 |
| (12.2) | % | 2.3 | % | ||||
Six months ended June 30, |
| ||||||||||||||||||
2020 | 2019 | % change |
| ||||||||||||||||
| Net |
| Oper. |
| Net |
| Oper. |
| Net |
| Oper. |
| |||||||
(Dollars in millions) | Sales | Income | Sales | Income | Sales | Income |
| ||||||||||||
Business Segments | |||||||||||||||||||
Safety and Industrial | $ | 5,603 |
| $ | 1,362 | $ | 5,900 |
| $ | 1,284 |
| (5.0) | % | 6.1 | % | ||||
Transportation and Electronics |
| 4,175 |
|
| 864 |
| 4,805 |
|
| 1,110 |
| (13.1) | (22.2) | ||||||
Health Care |
| 3,928 |
|
| 762 |
| 3,569 |
|
| 942 |
| 10.1 | (19.1) | ||||||
Consumer |
| 2,494 |
|
| 556 |
| 2,520 |
|
| 508 |
| (1.0) | 9.3 | ||||||
Corporate and Unallocated |
| (1) |
|
| 98 |
| 70 |
|
| (809) |
| — | — | ||||||
Elimination of Dual Credit |
| (948) |
|
| (239) |
| (830) |
|
| (197) |
| — | — | ||||||
Total Company | $ | 15,251 |
| $ | 3,403 | $ | 16,034 |
| $ | 2,838 |
| (4.9) | % | 19.9 | % | ||||
Three months ended June 30, 2020 |
| ||||||||||
Worldwide Sales Change | Organic local- | Total sales |
| ||||||||
By Business Segment | currency sales | Acquisitions | Divestitures | Translation | change |
| |||||
Safety and Industrial |
| (6.1) | % | — | % | (0.9) | % | (2.2) | % | (9.2) | % |
Transportation and Electronics |
| (18.9) | — | (1.1) | (0.9) | (20.9) | |||||
Health Care |
| (12.4) | 17.9 | (4.3) | (1.6) | (0.4) | |||||
Consumer |
| (5.0) | — | — | (1.2) | (6.2) | |||||
Total Company |
| (13.1) | % | 3.9 | % | (1.5) | % | (1.5) | % | (12.2) | % |
Six months ended June 30, 2020 |
| ||||||||||
Worldwide Sales Change | Organic local- | Total sales |
| ||||||||
By Business Segment | currency sales | Acquisitions | Divestitures | Translation | change |
| |||||
Safety and Industrial |
| (1.9) | % | — | % | (0.9) | % | (2.2) | % | (5.0) | % |
Transportation and Electronics |
| (11.1) | — | (0.9) | (1.1) | (13.1) | |||||
Health Care |
| (5.6) | 19.7 | (2.3) | (1.7) | 10.1 | |||||
Consumer |
| 0.3 | — | — | (1.3) | (1.0) | |||||
Total Company |
| (6.5) | % | 4.4 | % | (1.2) | % | (1.6) | % | (4.9) | % |
62
Sales by geographic area:
Percent change information compares the second quarter and first six months of 2020 with the same period last year, unless otherwise indicated. From a geographic perspective, any references to EMEA refer to Europe, Middle East and Africa on a combined basis.
Three months ended June 30, 2020 |
| |||||||||||||||
Europe, |
| |||||||||||||||
Asia | Middle East | Other |
| |||||||||||||
| Americas |
| Pacific |
| & Africa |
| Unallocated |
| Worldwide |
| ||||||
Net sales (millions) |
| $ | 3,633 |
| $ | 2,210 |
| $ | 1,332 |
| $ | 1 |
| $ | 7,176 | |
% of worldwide sales |
| 50.6 | % |
| 30.8 | % |
| 18.6 | % |
| — |
| 100.0 | % | ||
Components of net sales change: | ||||||||||||||||
Volume — organic |
| (16.6) | % |
| (7.8) | % |
| (15.2) | % |
| — |
| (13.6) | % | ||
Price |
| 1.0 |
| (0.3) |
| 0.7 | ||||||||||